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 Traumatic central nervous system (CNS) injuries lack effective treatment options and 
typically result in irrecoverable tissue damage and lifelong neurologic impairment. An ideal 
therapeutic would provide structural support for axonal regrowth as well as modulate the default 
secondary injury associated with CNS injuries. Extracellular matrix (ECM) bioscaffolds derived 
by decellularization promoted functional remodeling in numerous non-CNS applications; 
however, there has been minimal investigation of this technology in the CNS.  The objectives of 
this work were to evaluate the tissue specific properties of CNS-ECM in terms of (1) hydrogel 
characteristics and biochemical composition, (2) neurotrophic potential, and (3) ability to alter 
the innate immune response. 
Bioscaffolds composed of CNS-ECM were formed into injectable solutions that 
polymerize to form hydrogels at body temperature.  Hydrogels derived from CNS-ECM were 
compared to a hydrogel form of a non-CNS ECM, urinary bladder matrix (UBM-ECM), using 
compositional analyses for retained ECM molecules, mechanical assessments for rheological and 
turbidimetric properties, and multiphoton microscopy to visualize in-vitro three-dimensional 
neurite outgrowth.  ECM hydrogels from both tissue sources had mechanical properties similar 
to native CNS and supported three-dimensional neurite outgrowth.   
CNS-ECM and UBM-ECM bioscaffold mediated alteration of the innate immune and 
neural stem cell response was interrogated in-vitro using macrophages and spinal cord stem cells 
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(SPCs). While all ECM scaffolds evaluated decreased astrocyte differentiation, only UBM-ECM 
increased SPC neuronal differentiation.   Bioscaffolds derived from both CNS and non-CNS 
tissue sources promoted a pro-repair macrophage phenotype as demonstrated through 
immunofluorescent results.  Finally, CNS-ECM bioscaffolds were compared to UBM-ECM in a 
rat model of contusion spinal cord injury.  Macrophage polarization was evaluated over 4 weeks 
and a histologic evaluation of the lesion site completed.  While the ECM bioscaffolds did not 
improve functional recovery, pro-repair macrophages were found closely associated with the 
ECM injection sites. 
This body of work demonstrates CNS-ECM bioscaffolds can be isolated and are capable 
of minimally invasive injection, supporting neurite extension in-vitro, and modulating 
macrophage and stem cell responses. Future research is necessary to determine the added 
benefits that can be obtained when this technology is combined with others known to be 
beneficial for CNS tissue repair.   
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1.0  INTRODUCTION AND SPECIFIC AIMS 
Regenerative medicine therapies that actively harness innate healing mechanisms to promote 
tissue reconstruction are currently being implemented for the creation of non-traditional 
therapeutics that restore morphologically and functionally normal tissue.  Tissue engineering, a 
subset of regenerative medicine that takes advantage of traditional engineering techniques, 
commonly uses material scaffolds, cells, and bioactive molecules in application specific 
combinations to promote healing and functional tissue restoration.  While many techniques use 
synthetic and polymeric materials for tissue reconstruction, others take advantage of the natural 
extracellular matrix (ECM).  Through the process of decellularization, the ECM of a tissue is 
harvested and transformed into a bioscaffold that acts as a bioactive template capable of 
promoting site specific constructive remodeling in numerous preclinical and clinical 
applications. The unique ECM structure and molecular composition maintained by resident cell 
types of an organ are continually modified by a process termed dynamic reciprocity.  In this 
process, the cells that maintain the ECM alter their behavior in response to the current conditions 
of the ECM.  This, in turn, causes the cells to modify the structural and molecular composition of 
the ECM in a continuous feedback loop that adjusts for the current microenvironment.  It is 
logical then, that a bioscaffold derived from homeostatic tissue homologous to the site at which it 
will be applied may maintain structural and molecular components of the ECM that could 
influence the microenvironment and host response to promote reconstruction of functional tissue. 
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1.1 TRAUMATIC SPINAL CORD INJURIES 
Traumatic CNS injuries result in irrecoverable severe neurologic impairments, paralysis, and 
even death.  While the mechanisms following injury have similarities throughout the locations of 
the CNS, this dissertation will focus on injuries to the spinal cord.  Currently, approximately 1.3 
million people live with severe spinal cord injury (SCI) throughout the world (1) with an 
estimated additional 20,000 injuries occurring yearly (2).  Neurologic impairment and extent of 
lesion is highly dependent upon the injury location.  The spinal cord is segmented into four 
regions, cervical, thoracic, lumbar, and sacral, moving caudally along the rostrocaudal axis in 
accordance to the spinal cord nerves and the peripheral tissues they innervate.  Injuries leading to 
tetraplegia occur in a cervical segment of the spinal cord, whereas those with paraplegia 
sustained injuries in the thoracic, lumbar, or sacral portions of the spinal cord.  In the United 
States, tetraplegia accounts for 52.2% of injuries while incomplete or complete paraplegia result 
in 36.7% of injuries.  For tetraplegia the estimated lifetime cost of care is between 2 and 4.6 
million dollars, while the cost for paraplegics is between 1.4 and 2.2 million dollars (3), 
suggesting a strong clinical and economic need for a regenerative approach that can promote 
functional neurologic recovery. Traumatic injuries to the spinal cord occur in two injury phases, 
the primary insult, and the secondary injury. 
1.1.1 Primary and Secondary Injury 
The primary insult is most commonly a combination of the initial impact in conjunction 
with compression that results in cell death via hemorrhagic necrosis (4) and apoptosis (5, 6), 
disconnection of long fiber tracts and axons (7, 8), and demyelination (9-11).  Secondary injury 
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commonly includes (8) an inflammatory response (12), calcium mediated damage (13), 
glutamate excitotoxicity (14), vascular disruption (15), and apoptosis (5). In the later phase of 
secondary degeneration, Wallerian degeneration  occurs as  neurons and their myelin sheaths 
degrade rostral to the lesion site (16).  An astroglial scar is formed by tightly interwoven 
astrocytes attached by tight junctions and surrounded by proteoglycans (17).  In human SCI,  it is 
common to find relatively mild astroglial scars accompanied by mesenchymal scars composed 
primarily of collagen (16) that develop through the recruitment of meningeal fibroblasts (16). In 
addition to axonal degeneration and scar tissue deposition is the liquefractive tissue necrosis and 
formation of one of two forms of a lesion cavity.  The first form is a cyst surrounded by a thin 
astrogliotic wall and can be considered the final stage of healing.  The cyst commonly retains 
residual macrophages, small numbers of axons, bands of connective tissue, and blood vessels 
(16, 18).  The other cavity form is a syrinx that consists of a dense gliotic wall under pressure.  
The pressure may result in syringomyelia, enlargement of the cavity and compression of the 
surrounding parenchyma (19). While numerous secondary injury mechanisms contribute to the 
liquefractive tissue necrosis and cavity formation, this dissertation will focus on the roles of 
macrophages and microglia in this process.   
1.1.2 Macrophage and Microglia Response  
Macrophages and microglia are important contributors and mediators of the inflammatory 
environment in both acute and chronic SCI.  Although the cells have different developmental 
origins, their behavior following injury is classically considered similar and detrimental to the 
healing process.  Therefore, to overcome their detrimental behavior previous therapeutics were 
aimed at reducing the immune response rather than harnessing its role in tissue repair.  As both 
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macrophages and microglia play important roles in pro- and anti-inflammatory functions, it is 
logical that modulation of the cells towards a pro-remodeling phenotype could benefit wound 
resolution and constructive tissue remodeling.  The following section provides a brief overview 
of macrophages and microglia, including their origins, roles, and a dichotomy of behavior 
following SCI.   
1.1.2.1 Macrophage Origin  
Macrophages, part of the mononuclear phagocyte system, are derived from monocytes 
that develop from a common myeloid progenitor cell (20) in the bone marrow (21).  Progenitors 
originating in the bone marrow experience a cytokine cascade of granulocyte colony-forming 
unit and macrophage colony-forming unit that differentiate the cells to monoblasts, pro-
monocytes, and finally monocytes.  The monocytes then migrate from the bone marrow to the 
blood stream where they comprise of 5-10% of circulating blood cells.   Monocytes are then 
recruited from the blood stream in response to immune, metabolic, and pro-inflammatory stimuli 
(22).  In some tissues, monocyte recruitment also occurs to maintain sufficient populations of 
non-CNS tissue macrophages (23).  
 Peripheral blood monocytes are a heterogeneous population defined and categorized by 
Ly6C expression.  Ly6C+ monocytes exit the bone marrow and adopt the Ly6Cmid phenotype 
characterized by expression of CC-chemokine receptor 7 (CCR7) and CCR8 (24).  The Ly6C+/mid 
populations migrate towards inflammatory signals, exit the blood stream, and become 
macrophages that respond to clearance of pathogens and become involved in inflammatory 
resolution. The Ly6C- population plays a role in replenishing tissue macrophages (20). Many 
types of tissue macrophages have repopulation mechanisms to maintain independence from 
peripheral blood derived monocytes, however this is unique to each tissue and also can change in 
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a non-homeostatic state (23).  In the case of CNS phagocytic cells, which include microglia, 
perivascular macrophages, meningeal macrophages, and choroid plexus macrophages, there is a 
unique repopulation mechanism for each cell type.  Meningeal macrophages are rapidly 
repopulated, which suggests a bone marrow origin, while perivascular and choroid plexus 
macrophages repopulate in a slower fashion, indicating mechanisms independent of the 
peripheral blood system (25).  While some CNS macrophages may be derived from the 
peripheral blood myeloid system, the origin of microglia and their homeostatic repopulation 
appear to be in a closed system.  
1.1.2.2 Microglia Origin  
While microglia origin was originally believed to be of the same myeloid as 
macrophages, it has now been demonstrated that microglia are derived from primitive 
erythromyeloid progenitors that invade the brain from the embryonic yolk sac (26).  Microglia 
derive from macrophages in the yolk sac that have committed towards a macrophage lineage and 
have been described as participants of a second wave of primitive yolk sac hematopoiesis (27).  
Microglia again contrast other myeloid cell populations as the developmental transcription 
factors necessary for myeloid development are not required (28). This further stresses the notion 
that the microglial developmental program differs from peripheral tissue macrophages that 
microglia may have a behavioral skillset that diverges from peripheral monocytes and 
macrophages. Although there are several developmental differences between microglia and 
peripheral macrophages, the microglial repopulation mechanism has been a continued point of 
contention.  While many studies in the early 1990s agreed that the adult brain microglia 
population was sustained via peripheral blood derived macrophages (29, 30), it has since been 
shown that microglia are an independent population during tissue homeostasis (26, 31).  
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Conventional thought processes place this as differing from non-CNS tissues however, it has 
been seen that organs such as the liver, skin, and spleen, and lung also (23, 32) have self-renewal 
mechanisms independent of the myeloid system.    While during injury states, both traumatic and 
autoimmune, peripheral blood monocytes traverse the blood brain barrier become macrophages 
and strongly participate in the disease state, thus raising the question of how similar to a 
microglial cell a macrophage can become. 
Transgenic animal models exist to analyze the ability of macrophages to become 
microglial cells following microglial ablation. Mouse models of microglia removal, such as the 
CD11b-HSVTK transgenic model of microglial ablation (33), effectively remove these tissue 
macrophages from the CNS. Following microglia ablation the brain macrophage population is 
repopulated with CCR2+ monocytes from the blood stream.  While this suggests blood 
monocytes may have built in systems that can duplicate microglia behavior and phenotype, 
following 27 weeks in the CNS the monocytes cannot fully replicate microglia (33).  This speaks 
to the nature of microglia as an independent cell type from the peripheral myeloid cells.  The 
distinct behavior of microglia may be due to the complex milieu of signals in the CNS and the 
additional neurosignaling capacity microglia may have in comparison to their peripheral 
counterpoint.   
The early infiltration into the CNS provides primitive microglia with a continuous array 
of neural specific signals ranging from electrical stimulus to neurotrophic factors (34).  Microglia 
interaction with neurons and astrocytes also supports their integral role in the maintenance of 
neural structures (35).  During development, the close link between microglia and neurons 
allows microglia to interact with neuronal signals and, in part, mediate neuronal activity and 
function.  In fact, microglia play a significant role in development by participating in synaptic 
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stripping, a process of removing presynaptic junctions receiving weaker inputs neuronal 
connections during development (36).  This is partially completed using the CR3/C3 signaling 
complement components of the innate immune effector system in this process (37).  As these 
examples, among others, illustrate, there is a unique difference in functionality between 
microglia and peripheral macrophages. As another example, microglia are actively suppressed 
during homeostasis through the CX3CL1 (38) receptor, which differs significantly from 
peripheral monocytes and macrophages that are recruited through this mechanism.  Microglia 
may also secrete neurotrophic factors and play a role in CNS vascularization (39). The lack of 
histologic markers to distinguish the two cell types (other methods for distinguishing the roles of 
the two cell types include: cell sorting [CD45high, indicating macrophage, or CD45low, indicating 
microglia (40)], scanning electron microscopy [ruffled surface “rose aspect”, indicating 
macrophage,  or spikey, indicating microglia (41)], transgenic models (42, 43)) limits the ability 
to perform spatial analyses that could detail the contributions of the two cells to inflammation, 
constructive remodeling, and wound resolution.   
1.1.2.3 Macrophages and Microglia in SCI 
In homeostatic conditions microglia maintain a resting state ramified morphology (Figure 
1) that constantly monitor the environment (44) for serum proteins and abnormal 
neurotransmitter signaling such as damage signals (39).  Upon sensing a perturbation in the 
environment, microglia alter their morphology towards an amoeboid shape (45).  This 
morphology change can be classified as a shift towards a migratory phagocytic cell capable of 
engulfment and removal of injury debris, leaked blood parts, and micro-organisms (41, 46). 
Microglia can reach an injury site and begin to secrete pro-inflammatory cytokines such as IL-1β 
(47) as early as 30 minutes post injury (46, 48).  While it is assumed microglia play the 
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predominant role in the early pro-inflammatory secretions, without histologic markers capable of 
distinguishing between microglia and macrophages a non-transgenic model cannot make this 
assessment.  
 
 
 
Figure 1.  Resting state microglia in a ramified morphology in healthy CNS tissue.  Green = tomato lectin, 
200x magnification. 
 
While microglia respond immediately to the traumatic injury, it is hypothesized that 
much of the macrophage infiltration begins approximately 3 – 7 days post injury. At this point, 
increased concentrations of OX41 and ED1 positive cells can be found at the immediate lesion 
area (49, 50).  At this point, macrophages/microglia contribute to the pro-inflammatory milieu 
and are partially responsible for the secretion of TNF-α, IL-1β, NO, Superoxide, and hydrogen 
peroxide (51).  These pro-inflammatory molecules and reactions participate in cell death and 
ultimately lesion formation.  While the common perception is to view the macrophage response 
in only a negative manner, other research suggests that the peripheral macrophage response may 
be necessary for inflammatory resolution and deposition of site appropriate new ECM (52).   
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The immune response plays an important role in pro-inflammatory resolution and tissue 
healing through secretion of trophic molecules and ability to scavenge toxic factors (53, 54).  
Following injury in peripheral nerves, macrophages contribute significantly to wound resolution 
and healing (55).  While this macrophage contribution to SCI repair is not apparent, upon closer 
examination of the wound environment, it can be seen that monocyte derived macrophages 
participate in neurotrophic functions and neural repair (50, 56) . Through a novel chimeric mouse 
model, Michal Schwartz’s research group demonstrated an anti-inflammatory role provided by 
peripheral macrophages, but not microglia (42). This may suggest that microglia play a role in 
immediate debris clearance and bactericidal functions, while macrophages provide 
immunoregulatory signals via IL-10 to resolve harmful inflammation (57-59).  A subset of the 
monocyte derived macrophage population, CD11c+ (42), participated in this effect, which further 
identifies a distinct macrophage population that can contribute to spinal cord repair (60, 61).   
1.1.2.4 Dichotomy of Macrophage and Microglia Response 
The dichotomy of the macrophage response is well described in non-CNS tissues (62-66).  
Following injury, macrophages polarize along a response continuum ranging from the classically 
activated M1 macrophages to the alternatively, or regulatory, activated M2 macrophages. In 
response to the immunologic microenvironment, M2 macrophages are further divided into three 
subsets as shown in Figure 2 (63).   M1 macrophages are polarized via LPS/IFNγ (i.e. classically 
activated) and mediate tissue damage, initiate inflammatory (67-69)  response, and are 
responsible for pathogen resistance (70, 71).  M2 macrophages, polarized via IL-4, IL-10, IL-13/ 
IL-1R, are broken down into a subset of 3 types based on the polarization mechanisms.  M2a 
promotes Th2 responses and provides parasite resistance. M2b is involved in immunoregulatory 
functions and participates in IL-10 secretion (72). M2c is involved in immunoregulation, matrix 
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deposition, and tissue remodeling (20).  The M2 phenotype has recently been shown to be 
strongly associated with skeletal muscle regeneration (62).   
 
 
 
Figure 2. Markers, secreted products, and functionality of macrophages polarized towards a classic M1 or 
alternative M2 polarization state. Reprinted with permission from (63) with permission from Elsevier. 
 
In response to implanted ECM bioscaffolds and their degradation products, approximately 50% 
macrophages polarize towards M2 side of the spectrum (73).  This phenomenon has been shown 
to be an effective predictor for constructive tissue remodeling following injury (74).  The 
implantation of M2 macrophages also promotes nerve tissue remodeling in a sciatic nerve pre-
clinical model (66).  Mokarram et. al. demonstrated that macrophages polarized to the M1 end of 
the continuum through IFN-γ stimulation and M2 through IL-4 stimulation produce opposite 
effects on sciatic nerve reconstruction.  Nerve repair grafts implanted with IFN-γ to produce M1 
macrophages with showed diminished nerve repair whereas those treated with IL-4 to produce 
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M2 macrophages increased axons orders of magnitude higher than the non-cytokine treated 
scaffold.  While similar effects have been observed following spinal cord repair (75), the 
modulation of the immune system toward these beneficial effects has only recently been 
accepted as viable therapeutic options for treatment of CNS injury (76-78). While a similar 
polarization paradigm has been documented for microglia (79), no research has been completed 
to understand ECM bioscaffold mediated polarization on microglia. 
Macrophage Polarization in the Spinal Cord   
Following spinal cord injury, classic dogma dictated that the immune system played the 
predominant role only in pro-inflammatory secreting, secondary degeneration promoting, and 
multifaceted harmful invading cells that would be better removed than harnessed for any repair 
potential (80).  This idea has since evolved and grown to the understanding that the immune 
system plays a dual role and is involved in both CNS repair and injury (60, 81).  Implantation of 
macrophages, polarized with autologous skin (77) and peripheral nerve (78), promoted partial 
functional recovery following rat spinal cord injury.  Phase I clinical trials with polarized 
macrophage implantation showed the treatment as safe for use as a human SCI therapeutic as 
well as promoted partial bladder recovery in two patients (82).   Additionally, Kigerl et. al. 
demonstrated that following spinal cord injury, early macrophage and microglia infiltrate 
upregulated CD206 and arginase I (i.e. M2 phenotype markers) up to day 14 following injury 
simultaneously with their transcription of iNOS and CD86 (i.e. M1 phenotype markers).  While 
this phenomenon is highly diminished by 7-14 days post injury, it shows the natural presence of 
M2 macrophages following SCI, and points to the pro-inflammatory microenvironment as the 
cause for diminishing their presence.  Kigerl et. al. further stressed the importance of the 
microenvironment by implanting M2 macrophages into the center of the spinal cord lesion. As 
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hypothesized, M2 macrophages could not be found at the injury site several days post 
implantation, which may indicate the highly plastic cells (83, 84) were polarized into an M1 
state, thus diminishing the pro-regenerative effects, and questioning the benefits of implanting 
pushed macrophages at the injury site.  M2 macrophages and microglia have also been shown to 
promote remyelination (85), a critical factor in reconstructing the CNS. While these immune 
modulating therapies have reached clinical trials(82), their use has remained minimal and current 
treatments aim for patient stabilization and maintenance of tissue surviving injury. 
1.2 CURRENT TREATMENT 
Traumatic SCIs can produce injuries with irrecoverable neurologic outcomes and impairments.  
The current standard of care for new injuries is avoidance of hypotension and decompression of 
spinal cord impingements (86).  Additionally, the acute management of such injuries revolves 
around the use of immobilization, airway management, and reduction of impingement to 
promote spinal cord blood re-perfusion (87).  It was previously thought that pharmaceutical 
treatments designed to diminish the inflammatory response, such as systemic 
methylprednisolone (88), could reduce the chronic inflammation and secondary injury.  While 
such therapies provided initial promise (89, 90), results have since been shown to be variable and 
limited (91, 92).  Anti-immune therapeutics are now used sparingly by clinicians (93). 
Furthermore, it has since been demonstrated that the immune response is critical mediator in pre-
clinical models of regeneration (94). A regenerative medicine treatment that both alters the 
inflammatory response and promotes reconstruction at the site of injury would be a therapeutic 
advancement for the treatment of SCI.   
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1.3 EXTRACELLULAR MATRIX BIOSCAFFOLDS 
Bioscaffolds derived from naturally occurring extracellular matrix (ECM) scaffolds have been 
successful for tissue remodeling in a wide array of preclinical and clinical models.  The 
bioscaffolds that have been most commonly used include those derived from the porcine small 
intestinal submucosa (SurgisisTM), bovine dermis (TissueMendTM), human dermis (AllodermTM), 
porcine dermis (AllomaxTM), and porcine urinary bladder (MatristemTM).  Biologic scaffolds 
composed of ECM facilitated the constructive  remodeling of numerous tissues including 
esophagus (95, 96), lower urinary tract (97, 98), muscle and tendon (99, 100), and myocardium 
(101, 102), among others.  The successful use of these FDA-approved scaffolds to augment or 
replace injured tissues in clinical practice (103, 104) suggests that they may be a viable 
therapeutic for regenerative medicine approaches to SCI reconstruction. 
Both the compatibility and host response to ECM bioscaffolds are highly dependent upon 
decellularization and post-processing procedures (i.e crosslinking and terminal sterilization) 
(105).  Decellularization procedures can include a wide array agents and commonly include 
combinations of detergents, (i.e triton X-100, sodium dodecyl sulfate, sodium deoxycholate, and 
CHAPS), enzymes (i.e. trypsin, DNases, RNases), mechanical perturbation, acids (i.e. peracetic 
acid) , and bases (i.e. calcium hydroxide, sodium hydroxide), among others (106).  Incomplete 
decellularization treatments do not remove all cellular debris and result in a pro-inflammatory 
immune response (73, 107).  On the other end, while extreme procedures can effectively remove 
all cellular components, they often harm the ECM structure and decrease ECM scaffold efficacy.  
Thus decellularization protocols must be carefully optimized to understand in-vitro cellular and 
in-vivo host responses.  ECM post-processing techniques also modify the scaffolds and alter host 
response.  Crosslinked ECM bioscaffolds have been shown to be non-degradable and actively 
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promote a chronic inflammatory response that includes multinucleated giant cells (108). When 
comparing crosslinked versus non-crosslinked bioscaffolds decellularized using the same 
methodology, the non-crosslinked bioscaffold degrades releasing ECM degradation products and 
promotes constructive remodeling, while the crosslinked scaffold does not degrade.  Beyond 
crosslinking, terminal sterilization techniques including ethylene oxide, gamma irradiation, and 
E-beam can alter the scaffold (109).  These post-processing methods affect the structure of the 
ECM, and thus alter the constructive remodeling mechanisms.  
1.3.1.1 ECM Mediated Constructive Remodeling Mechanisms 
ECM mediated constructive remodeling occurs through multiple mechanisms that can 
alter the normal wound healing behavior to promote site appropriate tissue reconstruction.  A 
well created decellularization procedure maintains the ECM composition, including collagens, 
growth factors, and glycosaminoglycans, among others, which as the scaffold degrades releases 
degradation products and bioactive peptides that influence cell behavior.  The degradation and 
cryptic peptides enhanced perivascular stem cell regenerative potential through increasing 
proliferation and migration (110), influencing osteogenesis and bone remodeling (111), and 
recruiting endogenous stem cell populations in-vivo (99, 112).  Cryptic peptides may also 
modulate vasculogenesis (113) and play a role in the deposition of new, site-appropriate ECM 
molecules (114). Also maintained in the ECM bioscaffold, and possibly released during 
degradation, are growth factors that include VEGF (115), bFGF (116), and TGF-β1 (105).  
Molecules remaining in ECM bioscaffolds also promoting host tissue infiltration and participate 
in mechanotransduction.  Mechanotransduction has been shown to be a requirement for 
constructive remodeling of functional tissue in the urinary bladder (117) and tendon (118). In 
these models, when physiologic loading was removed (i.e. through the use of a catheter or 
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immobilizing cast, respectively), ECM scaffolds degraded and were not developed into site 
appropriate tissue.  Further mechanisms of ECM bioscaffold constructive remodeling include 
promoting innervation and modulation of the innate immune response. 
Innervation is partially mediated by the ECM (119, 120) and is a crucial factor for 
regeneration (121).  In several models of ECM bioscaffoldmediated c onstructive tissue 
remodeling, including the esophagus, skeletal muscle, and the abdominal body wall, innervation 
can be found in the reconstructed tissue along with functional smooth and skeletal muscle (122-
124).  Furthermore, ECM bioscaffold degradation products induced Schwann cell migration 
(122), which has the potential to recruit cells that play a major role in remyelination following 
injury.    While the ability to support infiltrating axons and functional innervation are integral for 
constructive tissue reconstruction following SCI, axonal regrowth cannot occur successfully in a 
non-permissive pro-inflammatory environment found following CNS injury.   
Macrophages are critical for constructive remodeling following ECM bioscaffold 
implantation, both through degradation and immunoregulatory functions.  Using a rat model of 
ECM mediated constructive remodeling in the abdominal body wall, Valentin et. al. 
demonstrated that depletion of macrophages severely limited ECM scaffold degradation, and did 
not lead to tissue repair (125).  Further investigation into the role of macrophages for tissue 
remodeling showed that properly produced ECM bioscaffolds promote a pro-regenerative M2, 
alternatively activated, macrophage phenotype (74). Thus, ECM bioscaffolds support cell 
infiltration and innervation, degrade to produce bioactive molecules that enhance stem cell 
regenerative potential, and alter the innate immune response towards functional tissue 
reconstruction.  These mechanisms behind constructive remodeling suggest that bioscaffolds 
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derived by decellularization of tissues and organs could be viable therapeutics for spinal cord 
repair.  
1.3.1.2 ECM Bioscaffolds Derived for Spinal Cord Repair 
Recent tissue engineering strategies have combined the use of acellular ECM 
bioscaffolds with cells or pharmaceuticals for use in CNS repair.  This dissertation focuses on the 
use of bioscaffolds derived from whole organs that maintain the complex mixture of ECM 
molecules found in the native ECM. Although the extent of ECM bioscaffolds in the CNS had 
been limited to dural repair (126, 127), recent experimental therapies have evaluated these 
bioscaffolds for SCI repair.  Xue et. al. evaluated acellular skeletal muscle ECM bioscaffolds 
seeded with amniotic epithelial cells in a hemisection model of SCI (128).  The bioscaffolds 
promoted moderate functional recovery, increased axonal sprouting, and remyelination.  Li et. al. 
examined acellular sciatic nerve constructs in combination with brain-derived neurotrophic 
factor in a transection model of SCI (129).  While functional recovery was not observed, 
retrograde axonal tracing indicated that the constructs created a permissive environment for 
axonal recovery.  Liu et. al. implanted acellular spinal cord ECM constructs seeded with 
mesenchymal stem cells in a hemisection model of SCI (130).  Both the acellular spinal cord 
constructs and those combined with mesenchymal stem cells showed moderate functional 
recovery, though there was no difference between the acellular and seeded scaffolds at 8 weeks.  
The results also showed an increase in remyelination. The experimental treatments detailed here 
were implanted in ahighly invasive model (hemi- or transection spinal cord injury) that may not 
be as clinically applicable as delivering these scaffolds in a non-invasive manner.  Although, 
while perhaps not as clinically relevant, these studies support the use of ECM bioscaffolds as 
therapeutics for CNS repair and begin to explore the use of organ specific ECM bioscaffolds as 
 16 
enhancements that further increase the efficacy of ECM scaffolds to promote tissue 
reconstruction. 
 
1.3.2 Organ Specific Bioscaffolds 
ECM bioscaffold success has been augmented through the use of site specific scaffolds derived 
from homologous tissue sources.  As cells interact with their ECM through reciprocal and 
dynamic interactions, cells shape ECM to be organ specific and tailored to the needs of the 
current physiologic state.  Thus, it is logical, that the use of ECM scaffolds derived from 
homeostatic tissue, homologous to that which it will be repairing, may contain signals and 
molecules necessary for organ recapitulation.  This topic has been demonstrated in several 
preclinical models, including, as previously discussed the spinal cord, but also the adrenal (131), 
lung (132, 133), and liver (134, 135). The use of an acellular spinal cord ECM bioscaffold 
promoted partial recovery in a rat model of hemisection spinal cord injury (130).  Acellular ECM 
bioscaffolds derived from adrenal tissue supported adrenocortical cell proliferation and 
maintained cortisol secretion (131).  Acellular scaffolds derived from the lung promoted 
differentiation of embryonic stem cells to lung specific cell phenotypes (136) and demonstrated 
in-vivo functionality (132).  Hydrogels derived from liver ECM supported liver specific 
sinusoidal endothelial function, whereas non-site specific scaffolds could not (134).  While these 
topics were cursorily evaluated by Liu et. al. (130)in some of the spinal cord ECM scaffolds for 
spinal cord injury, there has not been a systematic evaluation of the characterization and 
development of CNS-ECM bioscaffolds as therapeutics for CNS repair. Therefore the objective 
of the present dissertation is to evaluate the use of CNS-ECM bioscaffolds for the reconstruction 
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of CNS tissue.  This objective will be accomplished through the completion of three specific 
aims designed to interrogate the reconstructive potential of CNS-ECM. 
1.4 SPECIFIC AIMS 
SPECIFC AIM No. 1:  To decellularize CNS tissue and characterize the resultant CNS-
ECM.  
SUB-AIM No. 1-1: To develop and characterize the biologic and material properties of a 
hydrogel form of CNS-ECM. 
Rationale:  ECM is deposited by resident cells of each tissue and organ and the 
composition and structure is optimized for the maintenance of each respective tissue. Therefore it 
is plausible that ECM derived from the CNS has a unique composition or structure that may 
facilitate constructive remodeling of CNS tissue following injury (132-134, 136-140).   
Hypothesis1: Decellularized CNS tissue yields ECM contains a neurotrophic 
composition that can enhance neurite and support neurite outgrowth in three-dimensions. 
SPECIFIC AIM No. 2:  To determine the effect of CNS-ECM upon human peripheral 
blood macrophage phenotype and spinal cord stem cell regenerative potential in-vitro.  
Rationale:  Macrophage polarization is predictor of downstream remodeling and 
associated function following SCI (60); therefore an in-vitro determination of macrophage 
phenotype may provide insight into the in-vivo macrophage response to CNS-ECM (73, 74, 
125).  ECM bioscaffolds enhance the regenerative potential of perivascular stem cells, and may 
aid in promoting a similar response to a human derived spinal cord stem cell. 
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Hypothesis2:  Exposure to CNS-ECM induces an M2 regenerative phenotype in naïve 
macrophages and promotes human spinal cord stem cell mitogenesis, chemotaxis, and 
phenotypic maintenance.  
SPECIFIC AIM No. 3:  To evaluate regenerative potential of CNS-ECM in a rat model 
of contusion SCI.   
Rationale:  ECM scaffolds promote the recruitment of progenitor cells (99, 141), 
modulate the innate immune response (73, 74, 125), and degrade to generate bioactive molecular 
cues (142); all properties shown to be important for site-specific constructive tissue remodeling. 
Hypothesis3:  Following spinal cord contusion, local injection of CNS-ECM promotes 
M2 macrophage polarization and leads to tissue reconstruction. 
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2.0  BIOLOGIC SCAFFOLDS COMPOSED OF CENTRAL NERVOUS SYSTEM 
EXTRACELLULAR MATRIX  
2.1 INTRODUCTION 
The extracellular matrix (ECM) represents the secreted product of the resident cells of each 
tissue and organ and thus logically defines the ideal substrate or scaffold for maintenance of 
tissue specific cell phenotype. The ECM is a critical determinant of cell behavior and is known to 
affect intracellular signaling pathways, cell differentiation events, and cell proliferation among 
other important characteristics of tissue identity (132, 134, 136-139, 143, 144). These events are 
mediated through integrins and other cell surface receptors in response to ligands present within 
the ECM of every tissue (145-147). Subtle changes in ECM structure and mechanical properties 
can affect cell transcriptional events and associated cell phenotype and function (148, 149). 
Biologic scaffolds composed of ECM have been commonly used for the therapeutic 
reconstruction of many tissues including myocardium (150-152), kidney (153), lower urinary 
tract (154, 155), musculotendinous tissues (156-158), esophagus (96), and peripheral nerve 
(159), among others. There is clinical precedent for the application of ECM scaffolds in 
reconstruction of central nervous system (CNS) structures (127, 160), but the development of 
ECM scaffolds for CNS regenerative medicine strategies has received relatively scarce attention 
(161-163). It has been suggested that ECM harvested from specific tissues is the preferred 
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substrate for cells native to those respective tissues if maintenance of phenotypic characteristics 
is important (132, 134, 136-140). The methods by which ECM scaffolds are prepared vary 
greatly and such methods can markedly affect the composition, architecture, and material 
properties of the resulting construct (106, 164-166) as well as the host response following 
implantation (73, 107, 125, 167). Therefore, the methods of preparing ECM scaffolds intended 
for use in the repair and reconstruction of complex vital tissues such as heart, liver, kidney, and 
the CNS must be carefully considered as regenerative medicine strategies are developed for these 
tissues and organs. 
The objectives of the present study were to (1) develop a method for decellularization of 
a brain and spinal cord, (2) characterize the resulting CNS-ECM scaffolds in terms of 
composition and in vitro cytocompatibility, and (3) investigate potential tissue-specific 
advantages of CNS-ECM scaffolds compared to non CNS-ECM scaffolds by evaluating in vitro 
modulation of PC12 cell line mitogenesis, chemotaxis, and differentiation. 
2.2 MATERIALS AND METHODS 
2.2.1 Preparation of CNS-ECM 
Porcine brain and spinal cord tissues were obtained from animals (weight ~120 kg) at a local 
abattoir (Thoma’s Meat Market, Saxonburg, PA). Tissues were frozen (>16 h at 80°C), thawed 
completely, and separated from all non-CNS tissue. Dura mater was removed, and spinal cord 
tissues were longitudinally quartered and cut into lengths (<3 cm). The decellularization process 
consisted of a series of agitated baths: water (type I reagent water per ASTM D1193; 16 h at 
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4°C; 60 rpm), 0.02% trypsin/0.05% EDTA (60 min at 37°C) (Invitrogen Corp., Carlsbad, CA, 
USA), 3.0% Triton X-100 (60 min) (Sigma-Aldrich Corp., St. Louis, MO, USA), 1.0 M sucrose 
(15 min) (Fisher Scientific, Pittsburgh, PA, USA), water (15 min), 4.0% deoxycholic acid (60 
min) (Sigma), 0.1% peracetic acid (Rochester Midland Corp., Rochester, NY, USA) in 4.0% 
ethanol (120 min), PBS (15 min) (Fisher), water (15 min), water (15 min), and PBS (15 min). 
Agitation speed was 200 rpm for spinal cord tissues or 120 rpm for brain tissue with the 
exception of the initial step at 60 rpm. Decellularized spinal cord (Figure 3), and brain (Figure 4) 
were lyophilized and stored dry until use. 
 
 
 
Figure 3. Decellularized spinal cord, right, appears whiter in color than its lyophilized native counterpart 
(left). Ruler marks indicate 1mm. 
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Figure 4. Decellularized whole brain, right, appears whiter in color and less dense than its lyophilized native 
counterpart (left). Ruler marks indicate 1mm. 
2.2.2 Characterization of CNS-ECM constituents 
2.2.2.1 Characterization of residual DNA in CNS-ECM 
Qualitative assessment of residual DNA (106, 168) was conducted by fixation of non-
lyophilized ECM scaffolds in 10% neutral buffered formalin, which was then embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin (H&E) or with 40,6-diamidino-2-
phenylindole (DAPI). Quantitative analysis of DNA content and base pair length in the 
remaining CNS ECM was conducted by digestion of comminuted ECM with 0.1 mg/ml 
proteinase K solution (48 - 144 h). Protein was removed by repeated phenol/chloroform 
extraction and centrifugation (10,000g) until no white precipitate (protein) was observed at the 
interface, and the aqueous phase extract was mixed with 3 M sodium acetate and 100% ethanol. 
The solution was centrifuged to pellet DNA, and the pellet was rinsed with 70% ethanol, 
centrifuged, and dried. Double-stranded DNA was quantified using PicoGreen (Invitrogen) per 
kit instructions. Base pair length of residual DNA in CNS-ECM scaffolds was determined by gel 
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electrophoresis of DNA extracts on 1.0% agarose gel with ethidium bromide (2 h at 60 V) 
followed by imaging with ultraviolet transillumination. Decellularization was evaluated against 
established criteria: (1) absence of visible nuclei in H&E and DAPI stained sections; (2) no DNA 
fragments exceeding 200 bp in length; and (3) <50 ng dsDNA per mg lyophilized ECM (106). 
2.2.2.2 Protein content of CNS-ECM 
Unstained sections of native (non-decellularized) spinal cord, and brain and their 
respective ECM were deparaffinized, rehydrated, and stained for myelin via luxol fast blue (169) 
or immunostained for laminin via citrate antigen retrieval, blocking with 2% normal goat serum, 
incubation with rabbit anti-human laminin primary antibody (diluted 1:25; Sigma, L9393), 
H2O2, goat anti-rabbit IgG peroxidase-conjugated secondary antibody (diluted 1:400; Sigma, 
A0545), and diaminobenzidine (ImmPACT DAB substrate; Vector Laboratories Inc., 
Burlingame, CA, USA), followed by hematoxylin counterstaining and ethylene-xylene 
dehydration. 
Growth factors were extracted from 30 to 50 mg comminuted ECM per ml buffer by one 
of two methods. The first method used 50 mM Tris containing 2.0 M urea, 5.0 mg/ml heparin, 
and protease inhibitors, and the second method used 20 mM Tris containing 1.0% NP40, 10% 
glycerol, and protease inhibitors (105). Vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF) were assayed in urea-heparin extracts, while nerve growth factor 
(NGF) was assayed in NP40-glycerol extracts. Growth factors were quantified via Quantikine 
Human VEGF Immunoassay (R&D Systems Inc., Minneapolis, MN, USA), Quantikine Human 
FGF basic Immunoassay (R&D Systems), and NGF Emax ImmunoAssay System (Promega 
Corp., Madison, WI, USA) per manufacturer instructions. Primary and secondary extracts were 
obtained and assayed separately, with results summated. Growth factor analysis was indicative of 
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concentration but not activity. Urinary bladder ECM was prepared as described previously (142) 
and used as a reference material.  
2.2.3 In-vitro Characterization of CNS-ECM 
The pheochromocytoma-derived PC12 cell line (CRL-1721; ATCC, Manassas, VA, USA), a 
neoplastic rat cell line arising from neural crest tissue (170), was used as a model neural-like cell 
to evaluate in-vitro modulation of mitogenesis, chemotaxis, and differentiation by ECM derived 
from decellularized CNS tissues. Urinary bladder ECM was again used as a reference material 
(i.e. non-CNS tissue source) to determine whether CNS-ECM scaffolds offered any tissue-
specific advantages.  
For in-vitro cell assays, individual ECM samples were comminuted into particles (<1.0 
mm) and solubilized with 1.0 mg/ml pepsin in 0.01 N HCl (Fisher). Protein concentrations were 
assayed in multiple dilutes of solubilized ECM against a bovine serum albumin standard curve 
using bicinchoninic acid. Each pepsin-HCl ECM solution was neutralized to pH 7.4 with 0.1 N 
NaOH (Fisher), isotonically balanced with 10X PBS (Fisher), and diluted to desired 
concentrations with 1X PBS. Mitogenic and chemotactic effects of ECM on PC12 cells were 
assayed for a range of concentrations (2.5, 10, 25, or 100 mg protein per ml), and PBS and/or 
neutralized pepsin lacking ECM served as controls in all assays. All in-vitro assays were 
conducted as three or more replicates in triplicate or quadruplicate per condition. 
Undifferentiated PC12 cells (P5-9) were passaged at 30-90% confluence on flasks coated with 
poly-L-lysine (PLL) in complete culture medium containing RPMI 1640 supplemented with 10% 
heat-inactivated horse serum (Sigma), 5.0% fetal bovine serum (FBS; Thermo Fisher Scientific 
Inc., Waltham MA, USA), and 100 U/ml penicillin/100 mg/ml streptomycin (pen/strep). To 
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determine potential cytotoxic effects of ECM scaffolds, PC12 cells were plated on PLL-coated 
sterile glass coverslips at 70,000 cells per well in 12-well plates. ECM or PBS was added to the 
medium at 100 μg/ml 2 h after plating and cells were cultured for an additional 24 h.  
Cytocompatibility was determined using a Live/Dead Viability Kit (Invitrogen) per 
manufacturer instructions using 4.0 mM calcein AM and 4.0 mM ethidium homodimer-1. 
Viability of PC12 cells was quantified in fluorescence images using ImageJ (NIH) to split red 
and green channels, threshold, and count particles (cells), with binning to differentiate between 
cell clusters of various counts. The same ImageJ macro was used to analyze all images.  
Mitogenic effects of CNS-ECM scaffolds were determined by plating undifferentiated 
PC12 cells on PLL-coated 96-well plates at 4000 cells per well. After 12 h, ECM or PBS was 
added to each well and cells were cultured for another 20 h, followed by culture for 4.0 h with 5-
bromo-20-deoxyuridine (BrdU) and quantification of BrdU incorporation into PC12 DNA using 
a colorimetric BrdU cell proliferation ELISA (Roche Diagnostics Corp., Indianapolis, IN, USA) 
per manufacturer instructions. 
Chemotactic effects of CNS-ECM scaffolds were determined by transmembrane 
migration using blind-well chambers and polycarbonate filters with 8.0 mm pore size (AP48; 
Neuro Probe Inc., Gaithersburg, MD, USA). Filters were coated in 30 mg/ml laminin (Sigma) for 
30 min and allowed to dry completely. Undifferentiated PC12 cells were cultured to 70-90% 
confluence, starved overnight in RPMI 1640 supplemented with 1.0% FBS (Thermo Fisher) and 
pen/strep, trypsinized, and resuspended in unsupplemented 50:50 RPMI 1640:PBS. Each ECM 
was brought to concentration with PBS and diluted 50:50 with RPMI 1640, with 10% FBS in 
RPMI 1640 used to verify chemotaxis through each filter. Wells were loaded with 40,000 cells 
per well, and after 6 h each filter was removed, the upper (non-migratory) surface scraped, and 
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the lower (migratory) surface fixed with methanol, stained with DAPI, and imaged. Cells were 
quantified using ImageJ to threshold and count cells, with binning to differentiate between cell 
clusters of various counts. The same ImageJ macro was used to analyze all images. 
Differentiation effects of CNS-ECM scaffolds were determined by plating PC12 cells at 
low density (1500 cells per well) in PLL-coated 48-well plates. After 6 h for attachment, cells 
were starved for 16 h in 1.0% heat-inactivated horse serum with pen/strep. bFGF (171), ECM, or 
PBS was added 50:50 to medium in each well to obtain desired final concentrations, and cells 
were cultured for another 48 h followed by fixation with paraformaldehyde, permeabilization 
with 0.1% Triton X-100, actin staining with Fluorescein-conjugated phalloidin, and imaging with 
a Zeiss AxioObserver Z1 microscope. The percentage of differentiated cells was determined by 
manually quantifying cells with at least one neurite-like process longer than the soma diameter, 
with a minimum of 300 cells counted per well (172, 173). 
2.2.4 Statistical Analysis 
Graphical representations of all data show mean +/- standard deviation of at least three 
replicates, each conducted in triplicate or quadruplicate. Experimental groups depicted 
graphically as a pair were compared using a Student’s t-test. All other groupings were compared 
using one-way analysis of variance (ANOVA) with Tukey-Kramer post hoc analysis. Outliers 
greater than three standard deviations from the mean were excluded from data sets. 
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2.3 RESULTS 
2.3.1 Efficacy of Decellularization Method 
No residual nuclei were visible in H&E and DAPI images of ECM derived from spinal cord, or 
brain (Figure 5). Maximum fragment size of residual DNA in CNS-ECM scaffolds did not 
exceed 200 bp (Figure 6) (106). Quantification of dsDNA using PicoGreen showed that CNS-
ECM scaffolds retained <50 ng dsDNA per mg dry ECM (Figure 6). Concentrations of dsDNA 
were 37.9 ±7.7 ng/mg in spinal cord ECM and 40.2 ± 3.8 ng/mg in brain ECM.  
 
 
 
Figure 5. H&E and DAPI images of whole brain ECM and spinal cord ECM following decellularization.  The 
decellularized scaffolds are compared to their native counterpart to demonstrate decellularization efficacy. 
All decellularized images have been over exposed to demonstrate the lack of nuclei found post 
decellularization. 
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Figure 6.  Spinal Cord ECM and Whole brain ECM contain less than 50ng DNA/ mg ECM as denoted by the 
red line.  DNA remnants must less than 200bp to mitigate disease transmission 
2.3.2 CNS-ECM Constituents 
Histologic staining and immunohistochemistry showed that CNS-ECM scaffolds each retained 
laminin and myelin present in native tissues (Figure 7). Spinal cord ECM, and brain ECM also 
retained detectable concentrations of VEGF and bFGF, which were present in their tissues of 
origin (Figure 7). Concentrations of VEGF and bFGF in CNS-ECM scaffolds were comparable 
to concentrations in a non-CNS ECM scaffold derived from urinary bladder. In contrast, 
although all native CNS tissues contained NGF, spinal cord and brain ECM did not (Figure 8).  
 29 
  
 
Figure 7. Myelin was present in the native brain, native spinal cord, decellularized brain, and decellularized 
spinal cord as shown by luxol fast blue staining. Laminin was also present in brain ECM, spinal cord ECM, 
and their native counterparts as shown by immunohistochemistry with hematoxylin counterstain. 
Magnification is 100x. 
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Figure 8. Growth factor content of CNS-ECM scaffolds. Spinal cord ECM, brain ECM, and urinary bladder 
ECM retained detectable concentrations of VEGF and bFGF, while only native tissues contain NGF. 
2.3.3 In-vitro Characterization of CNS-ECM  
Spinal cord ECM and brain ECM were cytocompatible in-vitro, as was a non-CNS ECM derived 
from urinary bladder (Figure 9). Both CNS and non-CNS ECM scaffolds increased 
undifferentiated PC12 cell mitogenesis up to 1.5-fold in vitro at the concentrations tested (Figure 
10). CNS-ECM scaffolds induced PC12 chemotaxis in-vitro, resulting in up to 1.5-fold migration 
compared to unstimulated cells (Figure 11). In contrast, a non-CNS ECM scaffold attenuated 
migration to 0.5-fold control (Figure 11). Under the conditions assayed, CNS-ECM scaffolds 
induced PC12 differentiation at rates approaching 20% while a non-CNS-ECM scaffold induced 
differentiation at rates approaching 30% at an equivalent protein concentration (Figure 12). In 
summary, all PC12 cell functions except viability were modulated by CNS and non-CNS ECM 
scaffolds, including mitogenesis, chemotaxis, and differentiation. 
 31 
  
 
Figure 9. PC12 viability for CNS-ECMs and UBM-ECM is equivalent to the basal media control. 
 
 
 
Figure 10. Mitogenic effects of CNS-ECM scaffolds. Undifferentiated PC12 cell proliferation was modulated 
by spinal cord ECM, brain ECM, and urinary bladder ECM as determined by BrdU incorporation during 
PC12 cell mitosis. Increases in mitogenesis peaked at 53% (brain ECM, 25 mg protein per ml). * Indicates p < 
0.05 by one-way ANOVA.  
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Figure 11. Chemotactic effects of CNS ECM scaffolds. Undifferentiated PC12 cell migration was modulated 
by spinal cord ECM, brain ECM, and urinary bladder ECM as determined by trans-membrane PC12 cell 
migration. Changes in chemotaxis ranged from increases of 53% (brain ECM, 100 ug protein per ml) 
to decreases of 50% (urinary bladder ECM, 25 ug protein per ml). * Indicates p < 0.05 by one-way ANOVA. 
Figure 12. Differentiation effects of CNS-ECM scaffolds. PC12 neuronal differentiation induced by CNS and 
non-CNS ECM as indicated by neurite extension. Differentiation was compared using the following medium 
supplements: PBS as a negative control, spinal cord ECM at 100 μg/ml, brain ECM at 100 μg/ml, urinary 
bladder ECM at 100 μg/ml, or bFGF at 0.20 μg/ml as a positive control. *Urinary bladder ECM at 100 μg 
protein per ml induced greater differentiation than any other condition including the positive control (bFGF, 
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0.20 μg/ml). ** Spinal cord ECM or brain ECM at 100 μg/ml induced differentiation at rates comparable to 
the positive control which were greater than all other conditions except urinary bladder ECM at 100 μg 
protein per ml. ***Urinary bladder ECM at 10mg protein per ml induced differentiation at greater rates 
than the negative control (no ECM: 0mg/ml). # Differentiation rates increased with concentration for spinal 
cord ECM, brain ECM, and urinary bladder ECM (10 μg protein per ml vs. 100 μg protein per ml). 
Significant differences were determined between all groups shown by one-way ANOVA.  
2.4 DISCUSSION 
This study describes a versatile decellularization method that can be applied to two different 
CNS tissues: brain and spinal cord. The full protocol from tissue to ECM requires <24 h, a 
duration which compares favorably to previously reported CNS tissue decellularization methods 
(161-163). The resulting matrix is sufficiently acellular to obviate adverse host immune 
responses (73, 107, 125, 167) and contagion such as virus transmission (174-176) while retaining 
bioactive molecules, including myelin and laminin. In-vitro modulation of PC12 cell functions 
by CNS-ECM and the matrices’ retention of neurosupportive proteins as well as growth factors, 
including neuroinductive bFGF and the neurotrophin NGF, suggest that the materials might 
influence behavior of other neural and neural-like cells in vitro and in-vivo. 
Although the activity of growth factors, including neurotrophins, in CNS-ECM scaffolds 
is unknown, similar PC12 responses to CNS-ECM in-vitro suggests three nonexclusive 
possibilities: the amounts of NGF and other neurotrophins and growth factors (such as bFGF) 
with preserved bioactivity in each ECM are equivalent; spinal cord ECM and brain ECM contain 
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higher concentrations of neurotrophins other than NGF offset the lack of NGF; or, most likely, 
each CNS-ECM contains a unique profile of potent neurotrophins and growth factors which, in 
combination, yield similar effects.  
Previous reports of ECM scaffolds derived from CNS tissues (161-163) have not 
explored tissue-specific functionality of these materials in contrast to non-CNS ECM. The 
present study clearly shows distinct cellular responses to CNS versus non-CNS ECM scaffolds, 
including divergent chemotactic and differentiation effects but similar mitogenic effects. These 
results mimic the ability of other non-CNS ECM scaffolds to support site-appropriate cell 
phenotype in several complex tissues (132, 134, 137-139) and suggest unique capabilities for 
CNS-ECM that may prove useful in regenerative medicine applications within the CNS.  
Mitogenic and chemotactic effects of ECM scaffolds observed in this study were non-
linear and generally conformed to an inverted-U curve commonly observed in neural cell 
responses to stimuli (177-179). Increasing differentiation rates correlated with moderating 
mitogenic and chemotactic effects at higher ECM concentrations, suggesting a dose dependent 
shift in cellular responses. The establishment of ECM cytocompatibilities at 100 μg/ml, the 
highest concentration used for in-vitro assays, further reinforced the concept that higher ECM 
concentrations caused alterations in cell behavior rather than apoptosis or functional impairment. 
Increased differentiation that coordinated with increased mitogenesis and chemotaxis at the same 
ECM concentration may indicate sub-populations of PC12 cells that respond differently to the 
ECM scaffolds or may reflect the complexity of each ECM composition as it influenced behavior 
of pluripotent cells (170). In considering this phenomenon, it is important to note that the 
differentiation assay used unique conditions, including starvation medium, greater duration, and 
lower cell density. Overall, responses of PC12 cells to ECM scaffolds in-vitro suggest that these 
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materials might be used in-vivo to control neural cell plasticity without adversely affecting 
viability. 
Cell responses observed in this and other studies (110, 112, 136, 142, 144) suggest that 
ECM placed in-vivo has the potential (170) to attract endogenous progenitors such as neural 
stem cells to a site of CNS damage, induce proliferation, and cause differentiation into 
functional, site-appropriate cells to replace lost CNS tissue in cases of injury or 
neurodegenerative pathologies. If CNS-ECM proves to have advantages for in-vivo constructive 
remodeling of CNS tissues, then hydrogel forms of the scaffolds which crosslink in-situ would 
logically be desirable for minimally invasive application in the CNS. Ultimately and perhaps 
ideally, delivery of ECM (CNS or non-CNS) to a site of CNS injury in cases such as stroke or 
spinal cord injury might be achieved by localized injection of an ECM hydrogel (180) that would 
jointly fill the lesion, recruit endogenous stem cells, including neural stem cells, and enhance 
their regenerative responses (110). Hydrogel forms of ECM have been shown to induce rapid 
cell infiltration and site-appropriate constructive remodeling in vivo (152, 181). ECM 
bioscaffold remodeling in-vivo is likely to be further aided by the presence of VEGF and bFGF 
within the scaffolds, which suggests potential to promote neovascularization. Development of a 
microvascular network would not only support new tissue formation via transport, but could also 
deliver ECM degradation products as a signal to surrounding cells (110, 142), thereby inducing 
constructive remodeling and functional CNS recovery. 
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2.5 CONCLUSIONS 
Acellular biologic scaffolds can be derived from CNS tissues such as spinal cord and brain by a 
combination of enzymatic and chemical processing. These CNS-ECM scaffolds meet or exceed 
established decellularization criteria (106), are cytocompatible, and retain neurosupportive 
proteins and growth factors present within the tissues of origin that are known to modify neural 
cell behaviors. The resultant acellular biologic scaffolds are able to modulate behaviors of model 
neural-like cell as demonstrated by increased proliferation, migration, and differentiation of the 
PC12 cell line in-vitro over a range of concentrations. Contrasting PC12 cell migration and 
differentiation responses to CNS versus non-CNS ECM suggest tissue-specific functionality for 
biologic scaffolds in neural applications. Overall, results of the study suggest that CNS and non-
CNS ECM bioscaffolds may represent effective substrates for constructive neural tissue 
remodeling in-vivo and facilitate regenerative medicine approaches to CNS repair. Chapter 2 has 
been reprinted with permission from Elsevier (182). 
2.6 FUTURE WORK 
One metric not considered in this chapter was the age of the source tissue from which the ECM 
was harvested. The materials developed in this research were from market weight porcine. 
Previous studies have demonstrated that the age of the animal from which the material is derived 
is an important determinant of the success of the material.  In-vitro analyses of bioscaffolds from 
different source ages of small intestinal submucosa showed distinct differences in terms of 
mitogenic, and chemotactic properties, two metrics of regenerative potential (110).  Bioscaffolds 
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derived from the younger sources promoted increased chemotaxis, whereas those from the 
bioscaffolds derived from 26 and 52 week animals promoted increased mitogenesis (183).  When 
the bioscaffolds were evaluated in an in-vivo model of biocompatibility, bioscaffolds from the 
youngest animals promoted increased alternative macrophage activation and increase skeletal 
muscle formation within the ECM bioscaffold (184).   Bioscaffolds derived from the CNS, 
therefore, should be compared at different ages of development to enhance promotion of 
constructive remodeling.   
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3.0  HYDROGELS DERIVED FROM CENTRAL NERVOUS SYSTEM EXTRACELLULAR 
MATRIX 
3.1 INTRODUCTION 
Biologic scaffolds composed of extracellular matrix (ECM) can facilitate the constructive  
remodeling of numerous tissues including esophagus (95, 96), lower urinary tract (97, 98), 
muscle and tendon (99, 100), and myocardium (101, 102), among others.  Although the 
mechanisms by which ECM scaffolds promote a constructive and functional remodeling 
response are only partially understood, recruitment of endogenous multipotent progenitor cells 
(141, 142), modulation of the innate immune response (73, 74), scaffold degradation with the 
generation of bioactive molecular cues (112, 185, 186), and innervation (122) have all been 
shown to be important events in this process.  The contribution of the innate three-dimensional 
ultrastructure, unique surface ligand distribution, or molecular composition to constructive, 
functional remodeling is largely unknown.  However, hydrogel formulations of matrix scaffolds 
lack the native three dimensional ultrastructure of the source tissue but still possess in vitro and  
in vivo biologic activity (180, 187-191), suggesting that the molecular composition of these 
materials is an active factor in remodeling events.  There have also been reports that suggest 
tissue-specific biologic scaffold materials have properties that enhance greater site-appropriate 
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phenotypic cell differentiation compared to ECM scaffolds derived from non-homologous tissue 
sources (133, 134, 136, 182).   
The use of biologic scaffold materials within either the central or peripheral nervous 
system has not been extensively investigated (192).  However, it has been shown that innervation 
of remodeled scaffold materials is an early event when such materials are placed in several 
different anatomic locations and represents a predictor of constructive and functional outcomes 
(117, 122, 158).  It has also been shown that innervation is a critical event in robust regenerative 
responses that occur in species such as the newt and axolotl (121, 193, 194).  Methods for the 
isolation of central nervous system (CNS) ECM have recently been described.  The objectives of 
the present study were to develop a method to create hydrogel forms of brain and spinal cord 
ECM, examine the biomolecular composition and mechanical properties of the resulting 
hydrogels, and evaluate the in-vitro neural cytocompatibility and neurotrophic potential of CNS-
ECM hydrogels versus a hydrogel prepared from a non-CNS ECM; specifically, porcine urinary 
bladder matrix. 
3.2 MATERIALS AND METHODS 
3.2.1 Overview of Experimental Design 
Following decellularization of porcine brain and spinal cord, the resulting brain and spinal cord 
ECM (B-ECM and SC-ECM, respectively) were solubilized.  The ECM materials were analyzed 
for collagen and sulfated glycosaminoglycan content, ultrastructure, and hydrogel mechanical 
properties.  A commonly used neural cell line for examining neurite extension, N1E-115 (195, 
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196), was used to identify the neurotrophic potential of ECM hydrogels in two- and three-
dimensional culture. The results were compared to an ECM hydrogel manufactured from a non-
CNS source, porcine urinary bladder matrix (UBM-ECM) (180). 
3.2.2 ECM Biologic Scaffold Production 
Porcine brain, spinal cord, and urinary bladder were obtained from market weight animals 
(Tissue Source, Lafayette, IN). Tissues were frozen immediately after harvesting at -80°C, 
thawed  before use, and processed  by tissue specific methods described previously (Table 1A) 
(182).  In brief, CNS tissue was agitated (spinal cord tissue at 200 rpm; brain tissue at 120 rpm 
unless otherwise stated) in the following decellularization baths: deionized water (16 h at 4°C; 
60 rpm), 0.02% trypsin / 0.05% EDTA (60 min at 37°C; 60RPM; Invitrogen Corp., Carlsbad, 
CA, USA), 3.0% Triton X-100 (60 min; Sigma-Aldrich Corp., St. Louis, MO, USA), 1.0 M 
sucrose (15 min; Fisher Scientific, Pittsburgh, PA, USA), water (15 min), 4.0% deoxycholic acid 
(60 min; Sigma), 0.1% peracetic acid (Rochester Midland Corp., Rochester, NY, USA) in 4.0% 
ethanol (v/v; 120 min), PBS (15 min; Fisher), deionized water (twice for 15 min each rinse),  and 
PBS (15 min). Each bath was followed by rinsing the remaining tissue through a strainer with 
deionized water.  Decellularized B-ECM and SC-ECM were lyophilized and stored dry until use.  
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Table 1. Methods for Decellularization and Solubilizing B-ECM, SC-ECM, and UBM-ECM. 
 
 
 
UBM-ECM was prepared as previously described (197). In brief, connective tissue was 
removed from the serosal surface of the bladder. The tunica serosa, tunica submucosa, and 
majority of the tunica muscularis mucosa were mechanically delaminated, which left the 
basement membrane and tunica propria intact. Luminal urothelial cells were dissociated from the 
basement membrane by soaking the UBM-ECM in deionized water. The UBM-ECM was then 
agitated in 0.1% peracetic acid in 4.0% ethanol (v/v;  120 min; 300 rpm) followed by a series of 
PBS and deionized water rinses and lyophilization.  
3.2.3 ECM Digestion and Solubilization 
Lyophilized and comminuted B-ECM (20 mesh), SC-ECM (20 mesh or hand cut), and UBM-
ECM (20 mesh or hand cut; 400-1000μm largest particle dimension as measured by mesh 
diameter or ruler) were separately placed into a 0.01 N HCl solution containing 1mg/mL pepsin 
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(Sigma) at a concentration of 10 mg ECM/mL and stirred at room temperature for 48h as 
previously described (Table 1B) (180).  After 48h, B-ECM, SC-ECM, and UBM-ECM were 
completely digested and formed a pre-gel solution (pH~2).  The pre-gel ECM solution was 
brought to pH 7.4 using 0.01N NaOH and diluted to the desired volume/salt concentration using 
10x and 1 x PBS.  Pepsin is irreversibly inactivated at pH above 7.5 (198). 
3.2.4 Collagen and sGAG Quantification 
Collagen concentration of the pre-gel ECM solution was determined for samples from each 
production batch with the Sircol Assay Kit (Biocolor Ltd., UK) following the manufacturer’s 
recommended protocol (n=4 in duplicate or triplicate).    Sulfated glycosaminoglycan (sGAG) 
concentrations were determined using digested ECM at a concentration of 50 mg ECM/ml with 
0.1 mg/ml proteinase K (Sigma) in buffer (10 mM Tris–HCl, pH 8.0, 100 mM NaCl, 
25 mM EDTA for 48-72 hours at 50°C) using the Blyscan Sulfated Glycosaminoglycan Assay 
Kit (Biocolor Ltd., UK) and following the manufacturer’s recommended protocol (n=3 in 
duplicate or triplicate).  
3.2.5 Scanning Electron Microscopy 
Scanning electron microscopy was used to examine the surface topography of brain, spinal cord, 
and UBM-ECM hydrogels. Five hundred micron thick hydrogels were prepared and then fixed in 
cold 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) for 24 hours followed 
by three 30 minute washes in 1x PBS. Hydrogels were dehydrated in a graded series of alcohol 
(30, 50, 70, 90, 100% ethanol) for 30 minutes per wash, and then placed in 100% ethanol 
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overnight at 4°C. Hydrogels were washed 3 additional times in 100% ethanol for 30 minutes 
each and critical point dried using a Leica EM CPD030 Critical Point Dryer (Leica 
Microsystems, Buffalo Grove, IL, USA) with carbon dioxide as the transitional medium. 
Hydrogels were then sputter-coated with a 4.5 nm thick gold/palladium alloy coating using a 
Sputter Coater 108 Auto (Cressington Scientific Instruments, UK)  and imaged with a JEOL 
JSM6330f scanning electron microscope (JEOL, Peabody, MA, USA)  
3.2.6 Turbidity Gelation Kinetics 
Turbidimetric gelation kinetics were determined as previously described (199).  The pre-gel 
solution was diluted to 6mg/mL and maintained on ice at 4°C until placed into a 96 well plate 
(100μL/well).  The plate was immediately transferred to a spectrophotometer (Molecular 
Devices) preheated to 37°C, and absorbance was measured at 405nm every 2 minutes for 50 
minutes. Normalized absorbance was calculated using Equation 1 and then used to calculate the 
following parameters: time required to reach 50% and 95% maximum absorbance was denoted 
as t1/2 and t95, respectively, the lag phase, tlag, calculated by extrapolating the linear portion of the 
curve, and the turbidimetric speed, S, of gelation was determined by calculating the growth 
portion slope of the curve normalized to absorbance (180). The assay was repeated three times 
with independent samples in triplicate.   
 
 
 
Equation 1.  Normalized absorbance for turbidimetric analysis. 
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3.2.7 Rheological Measurements 
The pH of the ECM digest was neutralized to 7.4 and diluted to 4, 6, or 8mg ECM/ml.  The 
diluted pre-gel solution was then placed on a 40mm parallel plate rheometer (AR 2000, TA 
Instruments) at 1Pa stress and 10°C to ensure even distribution and the liquidity of the pre-gel 
solutions between the plates.  A dynamic time sweep was run with the parameters of 5% strain 
(with the exception of spinal cord ECM gel at 8mg/mL, which was run with 0.5% strain), 1 rad/s 
(0.159 Hz) and rapidly increasing temperature from 10°C to 37°C to induce gelation as indicated 
by a sharp increase and plateauing of the storage modulus (G’), and the loss modulus (G’’) (n=3 
per gel per concentration).  
3.2.8 N1E-115 ECM Cytocompatibility and Two Dimensional Neurite Extension 
N1E-115 mouse neuroblastoma cells (ATCC No. CRL 2263), a commonly used experimental 
cell line to examine neurotrophic potential and differentiation (195, 196), were cultured in 
DMEM (Sigma) with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham MA, 
USA) /1% pen/strep (Sigma) at a concentration of 100,000 cells per well in 12 well plate prior to 
the addition of ECM.  B-ECM, SC-ECM, or UBM-ECM digest was added after cell attachment 
at a concentration of 100μg ECM/mL. Following 18-24hrs in culture with ECM, the medium 
was removed and 4μM calcein-AM and 4μM ethidium homodimer-1 was added to each well to 
evaluate cytotoxicity.  Live cells that hydrolyze membrane-permeable calcein-AM, but not 
ethidium homodimer-1, fluoresce in green and dead cells that bind and activate ethidium 
homodimer-1, but not calcein-AM, fluoresce in red.   
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The effects of the B-ECM, SC-ECM, and UBM-ECM pre-gel digest upon N1E-115 
neurite outgrowth were independently evaluated and used as an indicator of neurotrophic 
potential of the remaining bioactive molecules in ECM materials after enzymatic degradation.  
N1E-115 cells in DMEM with 10% FBS/1%pen strep were seeded at a density of 5,000 
cells/well in a 24 well plate.  After incubation for 24h, the media was removed and replaced with 
DMEM with 2.5% FBS, which promoted low levels of neurite extension and allowed changes in 
response to ECM to be quantified. Neutralized ECM pre-gel solutions at concentrations of 
10μg/mL and 100μg/mL were added after cell attachment and cells were incubated for 48h. 
N1E-115 cells were fixed with 2% paraformaldehyde for 20 minutes at room temperature. 
Attached cells were stained with DAPI for nuclei and Alexa Fluor phalloidin 488 (Invitrogen) for 
F-actin filaments. Three images at 200x magnification were taken per well. The number of cells 
with neurite extensions were manually counted. The longest neurite of each cell was measured in 
pixels using ImageJ (NIH). The outgrowth assay was repeated six times per condition.  Neurites 
were denoted as cell processes that extended a minimum length of twice the diameter of the cell 
body.   
3.2.9 Neurite Extension in Three Dimensional Culture 
N1E-115 cells were maintained in 10% FBS DMEM media at 37°C.  B-ECM, SC-ECM, or 
UBM-ECM hydrogels (1ml) were cast with a cell density of 500,000 cells/hydrogel and a 
concentration of 6mg ECM/ml and after gelation for 1hr at 37°C in a non-humidified incubator. 
All hydrogels were then cultured for 24 hours in DMEM supplemented with 10% FBS/ 1% 
pen/strep. Serum concentration was reduced to 0% FBS and cells cultured for an additional 2 or 
7 days.  The hydrogels were then fixed with 4% paraformaldehyde (Fisher), stained for F-actin, 
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and imaged using multiphoton confocal microscopy to visualize three-dimensional cell 
morphology inside the hydrogel scaffolds.   
Hydrogels cultured with N1E-115 cells were stained with 0.1% Alexa Fluor 488 
Phalloidin (Invitrogen) for 2 hours and submerged in PBS solution in a hanging drop slide and 
coverslipped. To visualize neurite outgrowth in three dimensions, the slide was mounted beneath 
an Olympus FV1000 multiphoton system. The system was equipped with a Chameleon ultra-
diode-pumped laser, and a 25x XL Plan N objective with a N.A. of 1.05 and a field of view of 
500μm. The excitation wavelength was chosen at 830 nm at a 6% laser transmissivity.  The 
sampling speed was set to 2 μs/pixel with a 2 line kalman filter, and the scanning had an 
incremental z-step of 1 µm. Image stacks were then compiled into a maximum intensity z-
projection in ImageJ. Image stacks were imported into Imaris software (Bitplane, South Windsor 
CN, USA) for 3-D visualization. 
3.2.10 Statistical Analysis 
An independent Student’s t-test was used to compare the effect of ECM pre-gel digests on N1E-
115 cell differentiation to the effect of the no ECM control (p<0.05).  A one-way ANOVA was 
used for all other comparisons (p<0.05).   All statistical analysis methods used SPSS Statistical 
Analysis Software (SPSS, IBM, Chicago, IL, USA).  
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3.3 RESULTS 
3.3.1 Collagen and sGAG Quantification 
Collagen concentration of B-ECM was 537.5 ± 26.9 μg collagen/mg dry weight, which was less 
than SC-ECM and UBM-ECM at 703.2 ± 47.3 and 702.5 ± 113.5 μg collagen/mg dry weight, 
respectively (p< 0.01) (Figure 13A).  B-ECM and UBM-ECM had a higher sGAG concentration, 
5.1 ± 1.4 (p<0.009) and 4.4 ± 0.4 (p<0.02) μg sGAG/mg dry weight, respectively, compared to 
SC-ECM, which was 1.3 ± 0.9 μg sGAG/mg dry weight (Figure 13B).   
 
 
 
Figure 13. Collagen and sGAG composition in B-ECM and SC-ECM scaffolds.  (A) SC-ECM contains a 
significantly higher percentage of collagen than B-ECM.  (B) B-ECM contains a significantly higher 
concentration of sGAGs than SC-ECM. 
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3.3.2 Qualitative Assessment 
B-ECM, SC-ECM, and UBM-ECM pre-gel solutions polymerized to form a hydrogel at 
physiologic pH (7.4) and temperature (37°C). Qualitatively, SC-ECM hydrogels were more rigid 
than B-ECM and UBM-ECM hydrogels (Figure 14A-C).  SEM micrographs showed dense, 
moderately organized collagen fibrils in B-ECM, SC-ECM, and UBM-ECM hydrogels (Fig. 
14D-I). B-ECM contained the thickest fibrils (Figure 14G), while SC-ECM hydrogels contained 
the most dense arrangement of fibrils (Figure 14H).  SC-ECM and UBM-ECM hydrogels 
contained moderately organized collagen fibers, while B-ECM contained dense clusters of 
randomly distributed collagen fibers. 
 
 
 
Figure 14. B-ECM, SC-ECM, and UBM-ECM hydrogels and their respective Scanning Electron Micrographs 
(6mg/mL).  (A) B-ECM hydrogel; (B) SC-ECM hydrogel; (C) UBM-ECM hydrogel; (D) B-ECM 1000x; (E) 
SC-ECM 1000x; (F) UBM-ECM 1000x; (G) B-ECM 10000x; (H) SC-ECM 10000x; (I) UBM-ECM 10000x. 
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3.3.3 Turbidimetric Gelation Kinetics  
The gelation kinetics between hydrogel forms of B-ECM, SC-ECM, and UBM-ECM  were 
evaluated using a normalized absorbance (Figure 15A) to define the lag phase, times to reach 
half and 95% of the final turbidity, and speed to reach complete gelation using turbidimetric 
gelation kinetics as previously described (Table 2) (180, 199).  Turbidimetric gelation kinetics 
showed a sigmoidal shape for SC-ECM and UBM-ECM hydrogels, whereas B-ECM showed an 
exponential shape (Figure 15B).  Differences observed in kinetic curve shapes translated to a 
longer lag phase (tlag; Figure 15C) for UBM-ECM hydrogels (7.2 ± 1.4 min) than B-ECM (28 ± 
4.2 min) or SC-ECM hydrogels (3.6 ± 5.6 min).  The time required to reach half of the final 
turbidity (t1/2; Figure 15D) was also longer for UBM-ECM (11.0 ± 5.8 min.) than B-ECM (8.9 ± 
5.4 min) or SC-ECM hydrogels (8.2 ± 5.1 min.).  The time required to reach 95% of the final 
turbidity (t95; Figure 15E) was also longer for UBM-ECM hydrogels (21.6 ± 2.9 min) compared 
to B-ECM (15.1 ± 5.5 min) and SC-ECM hydrogels (12.2 ± 4.6 min).  The velocity to complete 
gelation (S; Figure 15F) was faster for SC-ECM hydrogels (0.11 ± 0.02 min-1) compared to B-
ECM (0.08 ± 0.01 min-1) and UBM-ECM (0.07 ± 0.02 min-1) (p<0.05). These results suggest 
that during hydrogel assembly, SC-ECM hydrogels reach the steady state plateau faster than B-
ECM or UBM-ECM hydrogels. 
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Figure 15. B-ECM and SC-ECM representative turbidimetric and normalized turbidimetric curves.  (A) 
Example absorbance curve and the metrics analyzed.  (B) Normalized absorbance for B-ECM (diamonds), 
SC-ECM (squares), and UBM-ECM (triangles).  (C) Lag time comparison for B-ECM, SC-ECM, and UBM-
ECM. (D) Time to 50% complete gelation for B-ECM, SC-ECM, and UBM-ECM. (E) Time to 95% complete 
gelation for B-ECM, SC-ECM, and UBM-ECM. (F) Velocity to complete gelation for B-ECM, SC-ECM, and 
UBM-ECM following the lag time. 
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Table 2. Summary of Rheologic and Turbidity Values for B-ECM, SC-ECM, and UBM-ECM. * Indicates 
statistical significance at p<0.05 when one group is statistically different from the other two. 
 
 
 
3.3.4 Rheologic Measurements  
The storage modulus (G’) and the loss modulus (G’’) for B-ECM, SC-ECM, and UBM-ECM 
hydrogels changed over time as the sample temperature increased rapidly from 10°C to 37°C.  
Sigmoidal storage and loss moduli curves showed increased maximum storage modulus, 
maximum loss modulus, and time to complete gelation as concentration increased (Figure 16A-
C).  SC-ECM hydrogels had the largest storage modulus at all hydrogel concentrations (Figure 
16D).  At 8mg/mL, the storage modulus for SC-ECM, 757.0 ± 74.8 Pa, was greater than both 
UBM-ECM and B-ECM (p <0.05), which showed storage moduli of 143.8 ± 84.1 Pa and 61.8 ± 
11.0 Pa, respectively.  While B-ECM hydrogels have lower storage moduli than SC-ECM and 
UBM-ECM hydrogels, B-ECM hydrogels at a concentration of 6mg/mL reached the steady state 
plateau in 2.4 ± 1.3 min.; a time that was faster than UBM-ECM and SC-ECM, which had times 
of 8.5 ± 1.7 min. and 7.0 ± 3.6 min., respectively.  Table 2 summarizes the storage modulus, loss 
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modulus, and time to complete gelation for each ECM hydrogel at concentrations of 4, 6, and 
8mg/mL.   
 
 
 
Figure 16. Representative rheologic gelation kinetics for B-ECM and SC-ECM hydrogels (4, 6, and 8 
mg/mL).  G’ represents the storage modulus and G’’ represents the loss modulus.  SC-ECM is significantly 
stiffer than B-ECM at each hydrogel concentration. (A) Storage modulus time sweep for B-ECM, SC-ECM, 
and UBM-ECM at 8mg/mL.  (C) Storage modulus time sweep for B-ECM, SC-ECM, and UBM-ECM at 
6mg/mL.  (C) Storage modulus time sweep for B-ECM, SC-ECM, and UBM-ECM at 4mg/mL. (D)  Final 
storage modulus for B-ECM, SC-ECM, and UBM-ECM at each concentration. * Indicates statistical 
significance of p<0.05. 
3.3.5 N1E-115 ECM Cytocompatibility and Two Dimensional Neurite Extension 
The live/dead assay showed all ECMs to be non-cytotoxic for N1E-115 cells (Figure 17). B-
ECM, SC-ECM, and UBM-ECM pre-gel solutions at concentrations of 10 and 100μg ECM/mL 
increased the number of cells extending neurites (differentiated cells) compared to cells cultured 
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without ECM digest.  At 100μg ECM/mL, SC-ECM digest promoted the highest percentage of 
differentiation, with 69.7 ± 14.0% of the cells extending neurites, whereas UBM-ECM and B-
ECM promoted, 57.4 ± 12.1% and 54.3 ± 11.7% respectively.  At 10μg and 100μg ECM/mL, B-
ECM, SC-ECM, and UBM-ECM increased the percentage of cells with neurite extensions 
compared to the buffered control; however B-ECM was the only scaffold that showed an 
increase in neurite extension length for both 10 and 100μg ECM/ml compared to cells cultured 
without ECM (Figure 18). 
 
 
 
Figure 17. Live/dead cytotoxicity analysis for B-ECM, SC-ECM, and UBM-ECM.  (A) B-ECM, (B) SC-ECM, 
and (C) UBM-ECM pre-gel solutions are non-cytotoxic when added to culture medium of N1E-115 cells (10x; 
scale bar is approximately 200 μm ). 
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Figure 18. B-ECM and SC-ECM pre-gel solutions increase the number of cells with neurite extensions.  All 
Scaffolds show a dose dependent increase for the number of cells with neurite extension, while only B-ECM 
shows a dose dependent increase in neurite length with increasing concentrations of ECM. * Indicates 
statistical significance of p<0.05. 
3.3.6 Neurite Extension in Three Dimensional Culture 
B-ECM, SC-ECM, and UBM-ECM supported the formation of three-dimensional neurite 
extensions at 2 and 7 days following removal of serum (Figure 19).  N1E-115 cells seeded in B-
ECM hydrogels promoted a short arborizing growth pattern at two days, while SC-ECM and 
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UBM-ECM hydrogels induce unipolar extensions.  By 7-days, all ECM hydrogels promoted 
unipolar or bipolar extensions (Figure 19).   
 
 
 
Figure 19. Neurite Extension in B-ECM, SC-ECM, and UBM-ECM in 6mg/mL hydrogels in a 3-D cube or 
compressed Z-stack.  (A)  N1E-115 cell extension following 7 days culture in B-ECM in 3-D cube.  (B) N1E-
115 cell extension following 7 days culture in SC-ECM in 3-D cube.  (C) N1E-115 cell extension following 7 
days culture in UBM-ECM in 3-D cube.  The compressed Z-stack shows B-ECM has short arborizing 
extensions at two days, while SC-ECM and UBM-ECM have uni- or bi-polar extensions.   At 7 days all ECM 
hydrogels support uni- or bi-polar N1E-115 cell extensions.  For 3-D cubes the major tick mark represents 
50μm and the minor tick mark represents 10μm.  For the Z-stacks the scale bar represents 50μm. 
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3.4 DISCUSSION 
The present study shows that biologic scaffolds derived from porcine brain and spinal cord can 
be processed to form hydrogels that retain selected ECM-specific constituents.  At comparable 
ECM concentrations, these hydrogel forms of CNS-ECM have distinctive composition and 
biomechanical properties. Furthermore, CNS-ECM hydrogels are cytocompatible, promote N1E-
115 cell differentiation, and support three-dimensional neurite extension. 
The mechanical properties of SC-ECM hydrogels are similar to those previously shown 
to support neuronal differentiation of stem cells (0.1-1kPa) (200). It is therefore plausible that the 
rheologic and turbidimetric properties of CNS-ECM hydrogels could be used to influence the 
differentiation of endogenous or therapeutically administered stem cells following CNS injury 
(200).  The gelation kinetics and storage moduli of CNS-ECM hydrogels can be manipulated to a 
certain extent by varying ECM concentrations, such that following polymerization a hydrogel 
could be made with tailored  in-vivo pre-polymerization lag time, final storage modulus, and rate 
of polymerization (201).  Altering these parameters may enhance not only the ability of the gels 
to modulate stem cell behaviors, but also the cell and drug delivery properties of CNS-ECM 
hydrogels (202, 203).   
It is logical that the distinctive collagen and sGAG concentrations play a role in ECM 
hydrogel gelation and rheologic properties; therefore, quantification of the collagen and sGAG 
concentrations provides valuable insight.  Furthermore, the collagen monomers aggregate and 
self-assemble into thin filaments that can then crosslink into collagen fibers that interweave with 
themselves and other ECM components to contribute to hydrogel formation (204).  The shorter 
polymerization time and smaller storage modulus of B-ECM hydrogel compared to SC-ECM 
hydrogel may result from the higher sGAG concentration found in B-ECM hydrogels. 
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Concentration of sGAGs has been shown to alter gelation kinetics and mechanical properties of 
hydrogels (205, 206).  While UBM-ECM hydrogel has a similar concentration of sGAGs 
compared to B-ECM hydrogel, the increased storage modulus could be due to a possible 
increased ratio of collagen I to collagen III in UBM-ECM hydrogel (207, 208). The increased 
storage modulus of SC-ECM hydrogel compared to UBM-ECM hydrogel may result from 
relatively low sGAG concentration found in SC-ECM. Although collagen composition of B-
ECM contains approximately 50% collagen, native brain contains very limited amounts of ECM 
components including collagen (209).  It should be noted that the percent collagen described 
herein represents a percentage of the isolated ECM, rather than a percentage of the mass of the 
intact brain prior to decellularization.  While collagen and sGAGs affect hydrogel mechanical 
properties, further studies are needed to determine those additional molecules present in the 
ECM hydrogels that may contribute to polymerization. 
Both composition and material properties of the CNS derived hydrogels are distinct from 
a hydrogel derived from a non-CNS tissue source (UBM-ECM)  (180).  The unique ECM 
composition of different organs (210, 211), suggests that ECM scaffolds derived from the same 
tissue type as that of the injury site may contain bioactive components uniquely able to induce 
constructive remodeling of that tissue type.  An array of proteins and peptides will be generated 
during ECM solubilization (142, 180) that is reflective of the molecular profile of the organ from 
which the ECM is derived.  Thus, a hydrogel derived from solubilized and digested CNS-ECM 
will contain a unique composition of molecular constituents resembling those found within the 
ECM of healthy CNS tissue.  The bioactive factors retained in the ECM hydrogels in the present 
study are neurotrophic as evident by the formation of N1E-115 cell neurite extensions when 
cultured in the presence of ECM digests. In addition, the present study shows that B-ECM 
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hydrogels increase the length of N1E-115 neurite extensions in two-dimensional culture.  This 
effect is not seen in UBM-ECM or SC-ECM digest, a possible indication of a tissue-specific 
effect of B-ECM upon these brain derived cells (195, 212). 
3.5 CONCLUSIONS 
B-ECM and SC-ECM hydrogels, while derived by similar decellularization methods from their 
source tissue, each have a unique biochemical composition, mechanical properties, and 
neurotrophic potential. The increase in neurite length for N1E-115 cells in response to B-ECM 
suggests a tissue specific effect of B-ECM hydrogels on a brain derived cell line.  Each ECM 
elicited unique cell responses as demonstrated by neurotrophic potential in their solubilized form 
and support of considerable three-dimensional neurite growth and extension in their re-
polymerized hydrogel forms; this finding suggests that the molecular constituents of the source 
ECM play an important role in the bioactivity of these scaffolds.  Support of three-dimensional 
neurite extension by CNS-ECM hydrogels also suggests the possibility that these hydrogels 
provide the scaffolding necessary to promote in-vivo axonal repair and warrants further study. 
3.6 FUTURE WORK 
Future research into hydrogels derived from the CNS for CNS repair should focus on evaluating 
functional neuronal networks within the hydrogel.  While this research evaluated hydrogel’s 
ability to support neurite extension in three-dimensions, there was no evaluation of the functional 
 59 
connections and functional networks that may have formed within the hydrogel. To accomplish 
this, primary neurons should be isolated and cultured within the hydrogels. Following 2-3 weeks 
in culture cells can be evaluated for expression of markers such synaptophysin (213) and 
evaluate GABA activation triggers (214).  Further, using three-dimensional multi-electrode 
arrays, it is possible to evaluate the ability of these isolated cells to excite spontaneously. By 
evaluating these metrics, further insight into the ability of the CNS-ECM hydrogel materials to 
impact neural repair will be developed. 
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4.0  ALTERNATIVE MACROPHAGE POLARIZATION AND ENHANCED NEURAL 
STEM CELL REGENERATIVE POTENTIAL WITH BIOSCAFFOLDS DERIVED FROM 
CENTRAL NERVOUS SYSTEM EXTRACELLULAR MATRIX  
4.1 INTRODUCTION 
The human central nervous system (CNS) has a limited capacity for repair (215), and the 
majority of severe traumatic CNS injuries yield neurologic deficits that lead to irrecoverable 
impairments.  While researchers have increased their understanding of the mechanisms behind 
CNS injury, clinical therapeutics that significantly improve neurologic impairments have not 
been developed (216).  Recent efforts have focused on the neural stem cell (NSC) and 
macrophage response as possible therapeutics capable of shifting the natural healing response 
towards one associated with tissue reconstruction. 
Following injury neural stem cells (NSCs) are pathotrophic (217) and migrate to the site 
of CNS trauma. NSCs can secrete neurotrophic factors that include nerve growth factor, brain-
derived neurotrophic factor, NT-3, and glial-derived neurotrophic factor, which may play 
important roles in wound resolution and mediating repair following injury (218).   NSCs also 
have been shown to play roles in remyelination (219) and may undergo neuro- and oligogenesis 
(220) under appropriate microenvironmental conditions.  Macrophage response following 
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traumatic CNS injuries can also mediate neural reconstruction and as such should be considered 
when developing neural reconstructive therapeutics.   
Macrophage response to traumatic CNS injury has recently been highlighted as a 
dichotomy of behaviors that can contribute to wound resolution and tissue repair (78)  or 
contribute to a pro-inflammatory environment (221).  Macrophages are highly plastic cells that 
respond to their microenvironmental signals along a response spectrum that ranges from the 
classic, M1 response, to the alternatively activated, M2 response (62, 63).  M1 macrophages are 
polarized via LPS/IFNγ and initiate pro-inflammatory (67-69)  responses and are responsible for 
pathogen resistance (70, 71).  M2 macrophages, polarized via IL-4, IL-10, IL-13 or IL-1R 
signals, promote Th2 responses, provide parasite resistance, mediate immunoregulation, 
participate in IL-10 secretion,  and deposit new ECM for functional tissue remodeling (20, 72).  
Following spinal cord injury (SCI) macrophages and microglia polarize towards the M1 
phenotype and greatly contribute to secondary injury.  Recently, it has been demonstrated that 
their contributions can shift towards the M2 phenotype and contribute to tissue repair and wound 
resolution if provided with a permissive microenvironment (60). A regenerative medicine 
therapeutic that can enhance the reconstructive potential of stem cells, as well as create a 
permissive environment for alternate activation of macrophages would be a significant 
advancement in therapies for traumatic CNS injuries.   
Bioscaffolds derived from the ECM of tissues and organs through decellularization have 
promoted site specific constructive tissue remodeling in several preclinical studies and clinical 
applications, including those of the peripheral nerve (159), dura matter (127), esophagus (95, 
96), lower urinary tract (97, 98), muscle and tendon (99, 100), and myocardium (101, 102), 
among others.  The success of these scaffolds is due, in part, to the ability to increase 
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regenerative potential and recruitment of stem cells (99, 110-112) and the modulation of the 
innate immune response towards an alternatively activated, pro-regenerative phenotype (73, 74, 
125, 222).  Furthermore, bioscaffolds derived from homeostatic tissue homologous to the wound 
site enhance maintenance of site appropriate cellular phenotypes (131, 134, 136, 186).  Recently 
ECM bioscaffolds have been derived from the CNS (161-163, 182).  A bioscaffold derived from 
homeostatic CNS tissue may contain site-appropriate molecular signals necessary for tissue 
reconstruction. Currently, these scaffolds have not been evaluated for their ability to enhance the 
reconstructive potential of clinically relevant human cell types.  The objectives of this work were 
to evaluate the ability of CNS-ECM scaffolds to (1) enhance human spinal cord stem cell’s 
(SPC) regenerative potential and (2) create a permissive microenvironment that promotes 
alternative, pro-regenerative, macrophage polarization.  The present study is focused on the 
mitogenic, chemotactic, and differentiation properties of CNS-ECM bioscaffolds in comparison 
to a non-CNS-ECM scaffold, urinary bladder matrix (UBM).    
4.2 MATERIALS AND METHODS 
4.2.1 UBM-ECM and CNS-ECM Scaffold Preparation 
4.2.1.1 UBM-ECM 
UBM-ECM was prepared as previously described.  In brief, porcine urinary bladders 
were harvested from market weight (240–260 lbs) pigs immediately following euthanasia. UBM-
ECM was prepared from the bladders using previously described methods (166, 223, 224). The 
connective and adipose tissue were trimmed and the tunica serosa, tunica submucosa, and 
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majority of the tunica muscularis mucosa were mechanically delaminated, leaving the basement 
membrane and tunica propria intact. Luminal urothelial cells were dissociated from the basement 
membrane by soaking the UBM-ECM in deionized water. The UBM-ECM was decellularized 
using a 0.1% peracetic acid/4% ethanol treatment with mechanical shaking at 300RPM. The 
UBM-ECM was then subjected to a series of phosphate buffered saline and deionized water 
rinses to ensure complete peracetic acid removal. 
4.2.1.2 CNS-ECM 
Immediately following euthanasia, whole brain and spinal cords were frozen at -80°C 
until use.  Whole brains with dura matter removed were sliced into 1cm³ cubes before placement 
in decellularization agents.  Whole spinal cords with dura removed were longitudinally quartered 
and cut into less than 3cm long segments. CNS tissue was mechanically shaken (spinal cord 
tissue at 200 rpm; brain tissue at 120 rpm unless otherwise stated) in the following 
decellularization agents: deionized water (16 h at 4°C; 60 rpm), 0.02% trypsin / 0.05% EDTA 
(60 min at 37°C; 60RPM; Invitrogen Corp., Carlsbad, CA, USA), 3.0% Triton X-100 (60 min; 
Sigma-Aldrich Corp., St. Louis, MO, USA), 1.0 M sucrose (15 min; Fisher Scientific, Pittsburgh, 
PA, USA), water (15 min), 4.0% deoxycholate (60 min; Sigma), 0.1% peracetic acid (Rochester 
Midland Corp., Rochester, NY, USA) in 4.0% ethanol (v/v; 120 min), PBS (15 min; Fisher), 
deionized water (twice for 15 min each rinse),  and PBS (15 min). Each bath was followed by 
rinsing the remaining tissue through a strainer with deionized water.  Decellularized B-ECM and 
SC-ECM were lyophilized and stored dry until use. 
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4.2.2 ECM Digestion and Solubilization 
Lyophilized and mechanically powdered B-ECM (20 mesh), SC-ECM (20 mesh or hand cut), 
and UBM-ECM (20 mesh or hand cut; 400-1000μm largest particle dimension as measured by 
mesh diameter or ruler) were separately placed into a 0.01 N HCl solution containing 1mg/mL 
pepsin (Sigma) at a concentration of 10 mg ECM/mL and stirred at room temperature for 48h as 
previously described (180).  After 48h, B-ECM, SC-ECM, and UBM-ECM were completely 
digested and formed a viscous pre-gel solution (pH~2).  The pre-gel ECM solution was brought 
to pH 7.4 using 0.01N NaOH and diluted to the desired volume/salt concentration using 10x and 
1 x PBS.  Pepsin is irreversibly inactivated at pH above 7.5 (198). 
4.2.3 Human Macrophage Description 
Human peripheral blood monocytes were isolated by negative selection (CD3, CD7, CD16, 
CD19, CD56, CD123 and Glycophorin A, Monocyte Isolation Kit II (Macs, Miltenyi Biotec)) 
from human blood obtained at a local blood bank.  Freshly isolated monocytes matured into 
macrophages (MΦ) over 7 days in RPMI media supplemented with 20% fetal calf serum and 
100ng/mL macrophage colony stimulating factor (M-CSF). To drive macrophages to the M1 
phenotype, macrophages were placed in RPMI media supplemented with 5% fetal calf serum and 
100ng/mL LPS (Sigma I3650) and 20ng/ml IFNγ (Sigma, I3275) for 24 hours.  To drive to an 
M2 phenotype macrophages were placed in RPMI media supplemented with 5% fetal calf serum 
and 20ng/mL IL-4 (PeproTech, 200-04) for 24 hours.   
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4.2.3.1 Human Macrophage Polarization with ECM Bioscaffolds 
Following monocyte maturation in MCSF, 250,000 naïve (MΦ) macrophages per well 
(24 well plate) were cultured in media supplemented with CNS-ECM pre-gel digests at 
concentrations ranging from 50μg/mL to 1mg/mL for 48 hours.  Cells were fixed with 2% 
paraformaldehyde and stained for M1 marker CCR7 staining and M2 marker CD206 to 
determine the polarization state induced by ECM scaffolds. 
4.2.3.2 Human Macrophage Chemotaxis 
Chemotactic effects of CNS-ECM bioscaffolds were determined by transmembrane 
migration using blind-well chambers and polycarbonate filters with 8.0 μm pore size (AP48; 
Neuro Probe Inc., Gaithersburg, MD, USA). Filters were coated in 5 μg/cm2 laminin (Sigma) for 
30 min and allowed to dry completely. Wells were loaded with 50,000 cells per well. After 
4hours in RPMI the filter was removed, the upper (non-migratory) surface scraped, and the lower 
(migratory) surface fixed with methanol, stained with DAPI, imaged, and quantified.  
4.2.4 Mouse Macrophage Description 
Mouse macrophages were isolated through the following established protocol as it has been used 
as a reliable and reproducible model for macrophage isolation.  In brief, mouse bone marrow was 
isolated and cultured with L929 fibroblast enriched MCSF media to mature myeloid precursor 
cells to mouse macrophages (225-227).  Before use, macrophage phenotype was confirmed with 
F4/80 (90% F4/80 positive), a standard mouse pan macrophage marker.   
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4.2.4.1 Mouse Bone Isolation 
Mice were euthanized with rapid cervical dislocation and sprayed with 70% ethanol.  A 
shallow incision was made on the leg severing the skin and exposing musculoskeletal tissue.  
Quadriceps were clamped for hip dislocation and distal femur was exposed. Mouse foot was then 
articulated to expose the tibia, excess tissue removed from the bone, and was placed on ice 
before bone marrow removal.   
4.2.4.2 Mouse Macrophage Culture 
Mouse macrophage complete media was added to a sterile petri dish and using 30 gauge 
needles the bone marrow rinsed out into sterile media until bone appears white.   Bone marrow 
aspirates were then centrifuged for 5 minutes at 1500 RPM and resuspended in 10mL of fresh 
mouse macrophage complete media.  Bone marrow aspirates were triturated to mix the pellet and 
strained through a 100 μm cell strainer and counted using a hemacytometer.  Cells were then 
placed in a 12 or 6 well plate, with 1 or 2 mL of cells per well, respectively, and incubated for 18 
hours at 37˚C. After 18 hours, an additional 1mL of macrophage complete media was added, and 
changed every 48 hours thereafter.  
4.2.4.3 Mouse Macrophage Polarization and Treatment with ECM Conditioned Media 
Seven days following bone marrow harvest and cell isolation, cells were treated with 
polarizing cytokines or media conditioned with UBM-ECM or CNS-ECMs (200 μg/mL).  M1 
macrophages were polarized with 20ng/mL IFNγ and 100ng/mL LPS (Miltenyi Biotec).  M2 
macrophages were polarized with 20ng/mL IL-4 (Miltenyi Biotec).  
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4.2.4.4 Mouse Macrophage Immunolabeling 
Following 18 hours in cytokine polarization or ECM conditioned media, media was 
aspirated and replaced with 2% paraformaldehyde for 20 minutes and rinsed thoroughly with 
1xPBS.  Cells were then blocked in 0.01% Tween-20, 0.01% Triton X-100, 2% Bovine Serum 
Albumin, and 2% Horse serum for 1 hour at room temperature.  Primary antibody incubation 
overnight at 4°C included, F4/80 (Abcam, AB6640) (rat anti-mouse; 1:200), iNOS (Abcam 
#ab3523) (rabbit anti-mouse; 1:100), Fizz1 (Peprotech, #500-P214) (rabbit anti-mouse; 1:200).  
Antibodies were chosen based on a literature search to determine markers that denote an M1 or 
M2 macrophage phenotype. Secondary antibody incubation for 45 minutes at room temperature 
included Alexa Fluor 488 (donkey anti- rat or rabbit; 1:200).  Nuclei were counterstained with 
500mM DAPI.  All wells were rinsed thoroughly with 1xPBS between staining solutions.   
4.2.5 Spinal Cord Stem Cell (SPC) Description 
Spinal cord stem cells were a kind gift from Dr. Jack Price at King’s College London and 
isolated with the following protocol (228). In brief 10 week old human spinal cord from the 
cervical region was finely chopped with a scalpel in 0.25% trypsin in DMEM:F12 at 37°C 
followed by 0.25mg/mL trypsin soybean inhibitor (Sigma). Cells were conditionally 
immortalized using a retroviral system with the cMYC-ERTAM gene (229).  Individual colonies 
were passaged using glass cloning cylinders (Sigma) and SPC-01 cell population was selected 
following over 20 uniform doublings.  Continuous cell culture was completed as previously 
described (228).  In brief, cells were grown on laminin-coated (Sigma-Aldrich), NUNC treated, 
tissue-culture flasks in DMEM/F12 supplemented with bFGF (10 ng/ml; PeproTech), EGF (20 
ng/ml; PeproTech), human serum albumin (0.03%; Baxter Healthcare), L-glutamine (2 mM; 
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Gibco); human transferrin (100 μg/ml; Sigma), putrescine dihydrochloride (16.2 μg/ml; Sigma) , 
human insulin (5 μg/ml; Fisher Scientific), progesterone (60 ng/ml; Sigma), sodium selenite (40 
ng/ml; Sigma), 4-OHT (100 nM; Sigma), and Pen/Strep (1%; Fisher Scientific) . Cell 
differentiation was triggered by the removal of growth factors and 4-OHT from the media. 
4.2.5.1 Spinal Cord Stem Cell Chemotaxis 
The migration response of SPCs to CNS-ECM degradation products was quantitatively 
evaluated with the Neuroprobe 48-well micro-chemotaxis chamber (Neuro Probe Inc. 
Gaithersburg, MD).  An 8 μm pore polycarbonate filter was coated with 20 μg/mL laminin for 1 
hour and dried completely.   B-ECM, SC-ECM, or UBM-ECM conditioned media was evaluated 
at concentrations of 50, 100, 250, 500 and 1000 μg/ml.  SPCs were added to the chamber at 
concentrations of 50,000 cells per well and incubated for 4 hours at 37°C. After 4 hours filters 
were fixed with methanol and stained with DAPI.  Experimental conditions were evaluated in 
triplicate three times. 
4.2.5.2 Spinal Cord Stem Cell Proliferation.  
SPC proliferation was determined through methods previously used to evaluate ECM 
products on perivascular stem cells (110).  The well-established 5-bromo-2’-deoxyuridine 
(BrdU) colorimetric assay (Roche, Nutley, NJ) was used.  Cells were plated at 5,000 cells/well in 
a 96 well plate with CNS-ECM pre-gel digest for 48hr.  Following this 48hr period, BrdU 
(10mM) was placed into the media to label proliferating cells. Plates were then fixed and 
manufacturer’s instructions followed.  Relative proliferation was quantified at 370nm and 492nm 
in a molecular spectrophotometer.  The assay was performed in triplicate for a total of three 
times. 
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4.2.5.3 Spinal Cord Stem Cell Differentiation 
Undifferentiated SPCs were plated in laminin coated wells at the following concentration 
at 25,000 cells per well in a 48 well plate (230).  Verification of stemness was completed before 
differentiation assays using Nestin and Sox2 (Figure 20).  The cells were allowed to attach to the 
wells for 24 hours.  Media supplemented with CNS-ECM or UBM-ECM digestion products was 
then replaced every two days and the cells fixed in 2% paraformaldehyde (230).  Cells were 
immunolabeled for β3-tubulin (1:200; Thermo-Scientific; MA1-19187) and GFAP (1:500; 
Abcam; 53554) to quantify neuronal and astrocyte differentiation. 
 
 
 
Figure 20. Prior to differentiation assays, SPCs were examined for their expression of neural stem cell 
markers Sox 2 and Nestin.  Transcription factor Sox 2 colocalizes with the nuclei of the SPC cells, while 
Nestin can be seen as an intermediate filament. 
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4.2.6 Cytocompatibility Analysis 
ECM cytocompatibility was evaluated using isolated human macrophages using an established 
live/dead assay.  In brief, 100,000 cells per well in a 48 well plate were cultured for 24 hours, at 
which time the media was replaced with ECM supplemented media at a concentration of 500 μg 
ECM/mL.  Cytotoxicity was evaluated for macrophages cultured with and without cytokines, and 
with ECM supplemented media.  Following 24 hours in culture with ECM, the medium was 
removed and 4μM calcein-AM and 4μM ethidium homodimer-1 was added to each well to 
evaluate cytotoxicity.  Live cells that hydrolyze membrane-permeable calcein-AM, but not 
ethidium homodimer-1, fluoresce in green and dead cells that bind and activate ethidium 
homodimer-1, but not calcein-AM, fluoresce in red. 
4.2.7 Statistical Analysis 
A one-way ANOVA was used for all comparisons (p<0.05) with a Tukey post-hoc for group 
comparisons.   All statistical analysis methods used SPSS Statistical Analysis Software (SPSS, 
IBM, Chicago, IL, USA).  
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4.3 RESULTS 
4.3.1 Cellular Cytocompatibility 
Live/dead assay assessed B-ECM, SC-ECM, UBM-ECM, and pepsin with M0, M1, or M2 
macrophages.  No scaffold exhibited a cytotoxic effect towards human macrophages, and  there 
was an approximately 98% or greater viability for human macrophages in the presence of ECM 
bioscaffolds (Figure 21).    
 
 
 
Figure 21.  ECM bioscaffolds are not cytotoxic to human monocyte derived macrophages. 
4.3.2 Macrophage Chemotaxis 
Table 3 summarizes the macrophage chemotaxis data towards each of the ECM scaffolds. Only 
UBM-ECM was the only ECM scaffold to contain degradation products capable of promoting 
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macrophage migration.  Naïve macrophages do not show significantly increased migration as 
compared to the pepsin digestion control (1.19 ± 0.14 and 1.24 ± 0.13 fold increase for 50 and 
500 μg, respectively). M1 macrophages do not show significantly increased migration as 
compared to the pepsin digestion control (1.26 ± 0.28 and 1.14 ± 0.17 fold increase for 50 and 
500 μg, respectively).  M2 macrophages promoted a significant increase in migration (p<0.05) as 
compared to the pepsin digestion control (2.91 ± 0.52 and 2.56 ± 0.40 fold increase for 50 and 
500 μg, respectively) (Figure 22). 
 
 
 
Figure 22.  Only M2 macrophages increase their chemotactic ability in response to UBM-ECM digestion 
products, suggesting an additional mechanism for how ECM scaffolds polarize macrophages at an injury site. 
* indicates a significant difference (p<0.05) compared to pepsin digestion buffer control. 
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Table 3. Summary of data for macrophage chemotaxis in response to SC-ECM, B-ECM, and UBM-ECM.  
Only UBM-ECM significantly increase migration.  Data expressed as fold change of cells migrated 
normalized to the pepsin digestion buffer. 
 
 
Mac. Polarization ECM Conc. Avg SC-ECM St Dev SC-ECM Avg B-ECM St Dev B-ECM Avg UBM-ECM St Dev UBM-ECM
M0 50μg/mL 1.07 0.54 2.10 1.36 1.19 0.14
M0 500μg/mL 1.40 0.68 1.40 0.98 1.24 0.23
M1 50μg/mL 0.80 0.11 1.47 0.65 1.26 0.28
M1 500μg/mL 1.03 0.31 3.30 2.27 1.14 0.17
M2 50μg/mL 1.04 0.59 1.47 0.48 2.91 0.52
M2 500μg/mL 1.34 1.03 1.72 0.75 2.56 0.40  
4.3.3 Macrophage Polarization  
Human monocyte derived macrophages were first evaluated for their ability to be polarized with 
CNS and UBM-ECMs.  These preliminary studies showed high variability and monocytes were 
subsequently used.  The monocytes were manipulated less prior to use, and this was 
hypothesized to decrease variability in cell surface marker expression (231). The polarization 
effect found with human monocytes showed similar trends to that shown in-vivo with UBM-
ECM, however with CNS-ECMs the variability was still increased, and a non-variable mouse 
model was then evaluated. 
4.3.3.1 Human Macrophage Polarization 
Moderate M1 polarization in response to CNS-ECM scaffolds with human monocyte 
derived macrophages, however this response was not significantly greater than the pepsin 
digestion control. Both B-ECM and SC-ECM showed two to three-fold increase in M1 
macrophage marker CCR7 expression, however the variability was too high in these cells to 
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draw significant conclusions. UBM-ECM did not show significantly increased M1 expression at 
any concentration (Figure 23).  
 
 
 
Figure 23.  Moderate M1 responses to B-ECM and SC-ECM after 48 hours in polarization. 
4.3.3.2 Human Monocyte Polarization 
The variability in polarization in response to all ECM conditioned medias was again 
increased (Figure 24).  Macrophages treated with UBM-ECM, however, showed the lowest 
variability among the ECM treated cells.  Further, the trend for these cells in response to UBM-
ECM treatment was towards an M2 phenotype as indicated by all UBM-ECM treated groups 
having averages below the pepsin digestion buffer control.  In response to the CNS-ECMs, there 
was a trend towards an M1 phenotype, however the cell surface marker expression was highly 
variable within each treatment group. 
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Figure 24.  Human Monocytes show a decreased M1 response as anticipated with UBM-ECM, however high 
variability makes interpretation difficult. 
4.3.3.3 Mouse Macrophage Polarization 
Mouse macrophage polarization was assessed using immunofluorescence. Fizz1 is an M2 
marker and iNOS is an M1 marker.  In this assay, a control polarization plate (Figure 25) was 
used to verify proper staining.  Once verified, the ECM test treatments were assessed.  In this 
assay, we saw consistent positive upregulation of Fizz1 expression for all ECM scaffolds, but not 
for pepsin (Figure 26).  B-ECM has the lowest percentage of Fizz1 positive macrophages, with 
only 36.70 ± 1.08 percent of the cells expressing Fizz 1 (Figure 27). SC-ECM, while containing 
the highest percentage of Fizz 1 expressing cells (59.89±19.9 percent), is the most variable 
among the ECM treated groups.  UBM-ECM, in comparison, polarizes almost 50% of the cells 
(44.88±2.10 percent) and maintains low variability.  This data suggests that there may be some 
mechanism conserved between the ECM of different tissues and organs capable of modulating 
macrophage behavior.    
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Figure 25.  Control plate for mouse macrophage staining shows positive M1 iNOS marker when macrophages 
are polarized with IFNγ/LPS and Fizz1 when polarized with IL-4.  
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Figure 26.  All ECM scaffolds exhibit M2 macrophage activation (via Fizz1 expression), however expression 
appears to be higher in UBM-ECM and SC-ECM as compared to B-ECM. The digestion buffer does not 
show iNOS or Fizz1 expression. 
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4.3.4 SPC Behavioral Response to ECM Bioscaffolds 
4.3.4.1 Chemotaxis 
SPCs increase chemotactic behavior by two-fold in response to 100 and 250μg/mL SC-
ECM (Figure 28).  This is markedly different from both B-ECM and UBM-ECM where 
chemotaxis is inhibited with increasing concentration reaching approximately a two-fold 
decrease in chemotaxis.  It is possible that this is a site specific response of these spinal cord 
stem cells towards SC-ECM (Figure 28). 
Figure 27. Quantification of mouse macrophage polarization shows that all ECM bioscaffolds promote an 
M2 polarization through an increase in Fizz1 expression with minimal M1 (iNOS) activation.  The digestion 
buffer control does not show an increase in either iNOS or Fizz 1. 
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Figure 28. SPCs respond to SC-ECM with an increase in migration, whereas to B-ECM and UBM-ECM, the 
SPCs exhibit a dose dependent decrease in migration. 
4.3.4.2 Proliferation 
SPCs exhibit differential mitogenic potential in response to CNS-ECMs and UBM-ECM 
as shown through the BrdU proliferation assay (Figure 29).  In response to UBM-ECM, 
mitogenesis not differ in comparison to the pepsin buffer.  However, there was a unique response 
to the CNS-ECM scaffolds.  In response to high concentrations of SC-ECM SPC mitogenesis 
decreases back to basal media levels and is significantly less than the pepsin digestion buffer 
control (p<0.05). In response to low concentrations of B-ECM mitogenesis has a significant 1.3 
fold increase (p<0.05) in comparison to the basal media and pepsin controls.  These results speak 
to the compositional and bioactive differences within the unique CNS-ECM scaffolds. 
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Figure 29.  SPCs exhibit differential effects in mitogenesis following exposure to ECM scaffolds.  In response 
to high levels of SC-ECM, mitogenesis is maintained at basal levels, whereas in response to high levels of B-
ECM, mitogenesis is increased. * indicates a significant increase in comparison to the pepsin and basal media 
controls.  # indicates a significant decrease in comparison to the pepsin digestion buffer control. 
4.3.4.3 Differentiation 
Following 21 days in culture with media conditioned with 250μg ECM/mL SPCs were 
stained for β3-tubulin denoting neuronal differentiation or GFAP denoting astrocyte 
differentiation.  While astrocyte differentiation remains constant between the CNS-ECM 
scaffolds, pepsin buffer, and the basal differentiation media (growth media with growth factors 
and 4-OHT removed), it was significantly decreased in the UBM-ECM group.  Also, UBM-ECM 
promoted significantly increased neural differentiation, where the CNS-ECM scaffolds did not 
(Figure 30). 
# 
* 
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Figure 30. Following 21 days in culture with media conditioned with 250ug ECM/mL SPCs were stained for 
B3-tubulin denoting neuronal differentiation or GFAP denoting astroglial differentiation.  UBM-ECM had 
significantly increased neuronal differentiation (# = p <0.05) and significantly decreased astrocyte 
differentiation (* = p<0.05) when compared to all other groups.  ECM conditioned media was at a 
concentration of 250 g ECM/mg. 
Spinal Cord ECM and pepsin, in rare occasions, produced GFAP+ cell populations with 
morphologies similar to reactive astrocytes (Figure 31) (232).  The hypertrophy was also similar 
to astrocytes commonly found after SCI (16). 
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Figure 31. Pepsin and SC-ECM occasionally produced GFAP differentiated cells with morphology commonly 
expressed by reactive astrocytes. 
4.4 DISCUSSION 
ECM bioscaffolds have been shown to promote functional constructive remodeling in numerous 
preclinical and clinical applications.  While several mechanisms mediate ECM bioscaffold tissue 
reconstruction, modulation of the endogenous stem cell response and polarizing the innate 
immune system towards a pro-reconstructive phenotype are paramount.  These mechanisms, 
among others, will be crucial for ECM bioscaffolds to mediate repair following traumatic CNS 
injury.   
Endogenous neural stem cell populations have been demonstrated in both the brain (233) 
and the spinal cord (234) and are known to contribute to population maintenance for both neural 
and glial cells (234). The regenerative potential of such cells is not currently harnessed to 
produce significant behavioral and cognitive recovery following injury.  Regenerative 
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therapeutics, such as ECM bioscaffolds, may harness the regenerative potential of such neural 
stem cells to promote neural recovery.  In this work, a spinal cord derived neural stem cell was 
evaluated in terms of mitogenesis, chemotaxis, and differentiation for CNS-ECMs and compared 
with properties of a non-CNS ECM, UBM-ECM.  Previous research demonstrated increased 
mitogenesis and chemotaxis of stem cells in response to ECMs (110), as well as recruitment and 
ultimately differentiation of multiple stem cell populations (99, 111, 112).  These results of this 
study confirm that ECM bioscaffolds may be able to not only recruit stem cells, but also to have 
mitogenic and differentiation capacities that can contribute to constructive remodeling following 
CNS injury. The SPCs in this study, demonstrated an increased chemotaxis towards an ECM 
derived from the spinal cord. This may suggest that SC-ECM retains specific neurotrophic 
factors following decellularization that these cells recognize as behavior altering molecules.  The 
decrease in mitogenesis with increasing concentration suggests that the cells may be undergoing 
a change in their molecular machinery towards differentiation.   
As stem cells begin differentiation, their rate of proliferation can decrease significantly 
(228).  The differentiation studies conducted in this work may add to the understanding of 
bioscaffold induced innervation.  CNS-ECM scaffolds promote an astroglial differentiation as 
demonstrated through GFAP staining, while UBM-ECM promoted neuronal differentiation.  
UBM-ECM and other bioscaffolds have induced innervation into newly reconstructed tissues, 
which may suggest that the highly innervated ECM of the bladder retains some component of the 
peripheral neural microvironemental niche following decellularization.  The work completed in 
this study suggests that ECM bioscaffolds may have the capacity to enhance the minimal 
regeneration found following CNS injury and promote tissue reconstruction. Alternatively 
activated macrophages also have been shown to increase the regenerative potential of neural 
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stem cells in addition to providing the necessary immunomodulatory milieu for wound resolution 
and tissue repair.   
This work evaluated the ability of CNS-ECM bioscaffolds to polarize human 
macrophages towards an alternatively activated state.  In-vitro studies of primary human 
macrophages can be highly variable, in part, due to high donor variation.  Variance may be 
increased as the monocytes are responding to both the tissue culture plastic (235) and the 
maturation cytokines that are known to alter macrophages from their M0 state (236).  The 
present study, then, evaluated human monocytes. The decrease in cell culture manipulation by 
using monocytes immediately after harvest can significantly reduce variation.  The polarization 
studies demonstrated effects of UBM-ECM scaffolds similar to the ratios seen in-vivo that are 
known to be a determinant for ECM mediated constructive remodeling. However, for CNS-ECM 
scaffolds the variance remained. To further understand the ability of CNS-ECM scaffolds to 
modulate macrophage phenotype in-vitro, we then used a non-variable mouse macrophage 
model.  This model demonstrated that, like UBM-ECM, the CNS-ECM scaffolds retain factors 
that can contribute to alternative macrophage activation and may possibly aid in CNS tissue 
reconstruction.  This study also furthered the understanding of macrophage response to ECM 
scaffolds through looking at their chemotactic effect. 
There is debate in the literature as to whether monocyte derived macrophages arrive to 
the site of injury in a pre-polarized state, or polarize upon interacting with the local 
microenvironment of a wound site.  While in reality it is likely a combination of the two theories. 
Following SCI, a subset of the monocyte population was shown to take a unique migratory route 
to the site of injury and subsequently was alternatively activated (237).  In the work of this 
manuscript, only M2 macrophages were shown to migrate towards UBM-ECM bioscaffolds.  
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This is an interesting concept as in-vivo, using an elegant radioactive tracking method for ECM 
degradation, ECM bioscaffolds were shown to begin degradation within the first 60 minutes and 
degradation products were found in the blood stream. This study may have demonstrated a 
unique method for an ECM mediated alternative macrophage response through recruitment of 
pre-polarized M2 cells from distal locations to the injury site.  Further research should evaluate 
peripheral blood macrophages and monocytes following ECM implantation a for M1 and M2 
polarization markers that could shed light onto this mechanisms of innate immune system 
modulation. 
4.5 CONCLUSION 
CNS-ECM bioscaffolds retain a unique molecular composition that alters the spinal cord stem 
cell differentiation, mitogenic, and chemotactic responses.  The neuronal differentiation potential 
of UBM-ECM may demonstrate a mechanism for innervation found following bioscaffold 
remodeling.  In addition, this work demonstrated an in-vitro model of human macrophage and 
monocyte polarization that matches in-vivo descriptions of the innate immune response towards 
ECM bioscaffolds.  The research here also demonstrated novel chemotactic responses of M2 
macrophages towards UBM-ECM, which may aid in the understanding of ECM bioscaffold 
induced mediation of the innate immune response.  In conclusion, this study furthers the 
understanding of ECM induced constructive remodeling and sets the foundation for future 
studies evaluating combinatory therapies that involve ECM scaffolds as cell or pharmaceutical 
delivery vehicles. 
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4.6 LIMITATIONS AND FUTURE WORK 
A significant limitation to this study was the limited markers to denote differentiation.  SPC 
differentiation only evaluated neuronal and astrocyte differentiation, and was only confirmed 
with 1 marker each. The next steps in the differentiation of these cells should be to evaluate 
maintenance of stem cell stemness or oligodendrocyte differentiation.  Further, the neuronal 
differentiation did not validate which type of neuron that the cells may have differentiated into, 
nor did the differentiation mark the cells as mature neuronal cells.  Thus future work should be 
done to discern a more complete differentiation profile of these spinal cord stem cells.   
In regards to the macrophage polarization, while it was limited to only 1 marker was used 
per M1 or M2 polarization, this was accounted for through evaluating several cell types in terms 
of macrophage polarization.  For future work in discerning macrophage polarization, a more 
functional descriptor should be used.  By evaluating in-vitro macrophage secretions in response 
to the ECM bioscaffolds (83), it would add insight into the mechanisms behind ECM mediated 
alternative macrophage polarization.  Furthermore, future work should evaluate the paracrine 
effects and cross talk between these two essential cell types.  This would set the foundation for 
research into macrophage, neural stem cell, and ECM combinatory therapeutics.   
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5.0  CONTUSION SPINAL CORD INJURY TREATMENT WITH INJECTABLE 
EXTRACELLULAR MATRIX BIOSCAFFOLDS  
5.1 INTRODUCTION 
Approximately 200,000 people live with spinal cord injury in the United States alone (238).  Of 
the estimated 20,000 new cases occurring each year, less than 1% of patients experience 
complete neurologic recovery by hospital discharge (2). Accompanying chronic paralysis are 
long term physiologic conditions that include chronic pain (239), depression (240), reduced 
bladder and bowel control (241, 242),   and  sexual dysfunction (243), among others.  SCI also 
leads to significant economic burdens on the patient and the healthcare system, with the 
estimated lifetime cost of care are between 2 and 4.6 million dollars for quadriplegics and 1.4 
and 2.2 million dollars (3) for paraplegics.  While much of the paralysis is due to the primary 
insult, secondary injury also contributes to tissue disruption. 
There are two mechanisms to spinal cord damage following severe SCI (244).  The 
primary injury consists of acute trauma to the spinal cord resulting in cellular necrosis (245) and 
vascular hemorrhaging (246), and secondary injury, which is composed of the sub-acute and 
chronic pro-inflammatory microenvironment that can lead to Wallerian degeneration.  Wallerian 
degeneration can include oligodendrocyte apoptosis (247), further axonal demyelination, and 
development of post traumatic syringomyelia (248).  The continued pro-inflammatory 
 88 
microenvironment is partially controlled by the macrophage and microglial response.  While 
macrophages and microglia can secrete molecules associated with tissue repair including TGF-
beta and arginase-1, following SCI the cells contribute to the secretion of TNF-α, IL-1β, NO, 
Superoxide, and hydrogen peroxide (51).  A regenerative medicine therapeutic that can alter the 
normal macrophage and microglia response could be beneficial following SCI. 
Regenerative medicine bioscaffolds composed of decellularized extracellular matrix 
(ECM) retain much of their native composition following removal of cellular and antigen 
components.  ECM bioscaffolds alter the innate response to injury towards and have promoted 
constructive tissue remodeling in several preclinical studies and clinical applications (95-102, 
127), in part, by modulation of peripheral macrophage response towards one correlated with 
tissue repair (73, 74, 125, 222).   Bioscaffold efficacy can be further enhanced when derived 
from homeostatic tissue homologous to the wound site (131, 134, 136, 186).  Recently, 
bioscaffolds have been isolated from CNS-ECM for use in CNS reconstruction applications 
(161-163, 182), however their application in preclinical models has been limited (130, 192). This 
study aimed to evaluate the histologic response towards implanted bioscaffolds derived from the 
brain and spinal cord as site specific materials in comparison to a well-established non-CNS 
ECM, urinary bladder matrix (UBM-ECM). A secondary objective of this study was to evaluate 
animal behavior over 28 days. 
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5.2 MATERIALS AND METHODS 
5.2.1 Overview and Experimental Design 
Sprague-Dawley rats underwent laminectomy and contusion injury.  Immediately following 
injury (less than 5 minutes), ECM bioscaffolds were injected into the center of the lesion site.  
Animals were then placed in behavior or histologic evaluation groups.  Histologic animals were 
sacrificed at days 7, 14, and 28 post injury for lesion site and macrophage analyses. Behavioral 
animals were preconditioned and evaluated for locomotor and sensorimotor recovery over 4 
weeks.    Results compared ECM bioscaffolds derived from the CNS, brain (B-ECM) and spinal 
cord (SC-ECM), to those derived from a non-CNS source, porcine urinary bladder (UBM-ECM). 
5.2.2 UBM-ECM and CNS-ECM Scaffold Preparation 
UBM-ECM, was prepared as previously described.  In brief, porcine urinary bladders were 
harvested from market weight (240–260 lbs) pigs immediately following euthanasia. UBM-ECM 
was prepared from the bladders using previously described methods (166, 223, 224). The 
connective and adipose tissue were removed and the tunica serosa, tunica submucosa, and 
majority of the tunica muscularis mucosa were mechanically delaminated, leaving the basement 
membrane and tunica propria intact. Luminal urothelial cells were dissociated from the basement 
membrane by soaking the UBM-ECM in deionized water. The UBM-ECM was decellularized 
using a 0.1% peracetic acid/4% ethanol treatment with mechanical shaking at 300RPM. The 
UBM-ECM was then subjected to a series of phosphate buffered saline and deionized water 
rinses to ensure all peracetic acid was removed from the tissue. 
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5.2.2.1 CNS-ECM 
Immediately following euthanasia, whole brain and spinal cords were frozen at -80°C 
until use.  Whole brains with dura matter removed were sliced into 1cm³ cubes before placement 
in decellularization agents.  Whole spinal cords with dura removed were longitudinally quartered 
and cut into less than 3cm long segments. CNS tissue was mechanically shaken (spinal cord 
tissue at 200 rpm; brain tissue at 120 rpm unless otherwise stated) in the following 
decellularization agents: deionized water (16 h at 4°C; 60 rpm), 0.02% trypsin / 0.05% EDTA 
(60 min at 37°C; 60RPM; Invitrogen Corp., Carlsbad, CA, USA), 3.0% Triton X-100 (60 min; 
Sigma-Aldrich Corp., St. Louis, MO, USA), 1.0 M sucrose (15 min; Fisher Scientific, Pittsburgh, 
PA, USA), water (15 min), 4.0% deoxycholic acid (60 min; Sigma), 0.1% peracetic acid 
(Rochester Midland Corp., Rochester, NY, USA) in 4.0% ethanol (v/v; 120 min), PBS (15 min; 
Fisher), deionized water (twice for 15 min each rinse),  and PBS (15 min). Each bath was 
followed by rinsing the remaining tissue through a strainer with deionized water.  Decellularized 
B-ECM and SC-ECM were lyophilized and stored dry until use. 
5.2.3 ECM Digestion and Solubilization 
Lyophilized and mechanically powdered B-ECM (20 mesh), SC-ECM (20 mesh or hand cut), 
and UBM-ECM (20 mesh or hand cut; 400-1000μm largest particle dimension as measured by 
mesh diameter or ruler) were separately placed into 0.01 N HCl solutions containing 1mg/mL 
pepsin (Sigma) at a concentration of 10 mg ECM/mL and stirred at room temperature for 48h as 
previously described (180).  After 48h, B-ECM, SC-ECM, and UBM-ECM were completely 
digested and formed a viscous pre-gel solution (pH~2).  The pre-gel ECM solution was brought 
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to pH 7.4 using 0.01N NaOH and diluted to the desired volume/salt concentration using 10x and 
1 x PBS.  Pepsin is irreversibly inactivated at pH above 7.5 (198). 
5.2.4 Spinal Cord Injury 
All animal surgical research was approved by the Institution of Animal Care Committee at the 
University of Pittsburgh.  Animals were placed under deep anesthesia with 60mg/kg ketamine 
HCl and 0.4mg/kg medetomidine throughout all surgical procedures.  Animals received a 
laminectomy at the T7-T10 vertebrae to expose the spinal cord.  Following cord exposure the 
animals were attached to the infinite horizon impactor (Precision Systems, IL) for piston 
contusion injury.  Contusion injuries within +/-5% of the 175kDyne injury were placed into one 
of 4 groups, B-ECM, SC-ECM, UBM-ECM, or pepsin control buffer.   Following contusion the 
animals were injected immediately with 5μL of the 8mg ECM/mL material or equivalent buffer 
from their respective group into the center of the spinal cord lesion.  Muscle overlaying the spine 
was sutured together and the skin closed with Michel wound clips.  A total of 8 animals per 
group were underwent surgical procedures for functional recovery and an additional 8 animals 
per group (4 for 1 week time point and 4 for 2 week time point) were contused and injected with 
bioscaffolds for histologic analysis.   
5.2.4.1 Post-surgical Animal Care and Euthanasia 
Following surgery animals were immediately given 1.5mg/kg atipamezole HCl to reverse 
the sedative effects, 10mL of Ringer’s solution, and 6mg/kg gentamicin intramuscularly.  
Animal bladders were expressed twice daily for 14 days and received 5mL Ringer’s solution 
(subcutaneously), 6mg/kg gentamicin (intramuscularly), and 0.03 mg/kg buprenorphine 
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(subcutaneously) daily 7-10 days post operation.    Animals were deeply sedated using 60mg/kg 
ketamine HCl and 0.4 mg/kg medetomidine, and 500IU of heparin was injected into the left heart 
ventricle prior to euthanization. This was followed by 300mL 1xPBS and 500mL of 4% 
paraformaldehyde.   Spinal cord was exposed via tissue removal and laminectomy along the 
cord.  Brain and spinal cords were placed in 4% PFA for 24 hours followed by 30% sucrose for 
an additional 24 hours and embedded in OCT.  
5.2.5 Immunofluorescence and Histochemistry 
Injured spinal cords were embedded in OCT leaving approximately 1cm proximal and distal to 
the lesion site.  Cords were cut into 12 series of 10μm thick horizontal sections and stored at -
20°C until histochemical or immunofluorescence processing.  Sections were stained with 
Masson’s trichrome or processed through a triple immunolabeling procedure to perform a 
temporospatial macrophage phenotype analysis. 
5.2.5.1 Macrophage Triple Immunolabeling 
Macrophages/microglia were immunolabeled for classically or alternatively using 
modified previously established methods (73).  In brief, the OCT embedded sections were rinse 
thrice in 1xPBS for 10 minutes per wash.  Following this, slides were incubated in blocking 
solution (0.01% Triton X-100, 0.01% Tween-20, 5% Horse Serum, and 2% Bovine Serum 
Albumin) for 45 minutes.  Primary and secondary antibody incubations were done using the 
blocking solution as the antibody diluent.  Primary antibody incubation included CD11b (mouse 
anti-rat; 1:250), pan macrophage/microglia, CD86 (rabbit anti-rat; 1:300), M1 marker, and 
CD206 (goat anti-rat; 1:250), M2 marker overnight at 4°C.  Secondary antibodies incubated (all 
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dilutions were 1:300) for 45 minutes at room temperature and included Alexa Fluor 488 donkey 
anti-goat, Alexa Fluor 594 donkey anti-mouse, and Percp Cy5.5 donkey anti-rabbit.  All slides 
were counterstained with DAPI and imaged using Nuance multispectral software (PerkinElmer). 
Between primary incubation, secondary incubation, and the DAPI counterstain the slides were 
rinsed thrice in 1xPBS for 10-15 minutes per wash. 
5.2.6 Behavioral Testing 
Prior to behavioral testing, all animals were given 3-5 habituation treatments that allowed them 
to equilibrate and become comfortable with their environment before evaluation. Throughout the 
behavioral testing, researchers directly performing the evaluation were blinded to the animal’s 
treatment group.  Blinding was accomplished using a double labeling system such that during 
surgery the animal was assigned an identifier that was then hidden during the injection.  The 
animal was then assigned a second identifier that related to the treatment group. The second 
identifier was then removed and the animal returned to the appropriate housing location.  Only 
the study coordinator had access to the key matching final identifiers to the treatment group.  The 
key was then released following completion of the behavioral testing and analysis. 
5.2.6.1 BBB 
Basso, Beattie, and Brennahan open field locomotor (249) examination evaluates 
complex kinematic movements of animals following SCI as they move around an open field.  
Animals were observed for 4 minutes at days 1, 3, 7, 14, 21, and 28 post injury.  The movements 
were evaluated according to the BBB examination criteria.  A healthy animal scores 21 points, 
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while a completely paralyzed animal scores a 0.  The scoring progresses as the animal regains 
limb control and function.   
5.2.6.2 Gridwalk 
Sensorimotor testing was evaluated using a horizontal ladder walk (250) that scores the 
animal based on the number of slip as the animal moves across the ladder.  Small (paw), medium 
(foot to the part of the lower leg), and large (whole leg) slips were counted during the 60 cm 
length at the middle of the ladder.  Results displayed as a percentage of steps to normalize 
between the number of steps varying by animal. 
5.2.6.3 Digigait 
While classic locomotion pattern is evaluated using an ink footpad (251), this experiment 
used a motorized treadmill and camera to track the motion of the footprints.  Through the 
Digigait analysis four metrics were assessed: individual paw stride length, paw angle of rotation, 
limb stance width, and step angle.    
5.2.7 Statistical Analysis 
A repeated-measures one-way ANOVA was used for statistical comparison for the BBB and 
gridwalk analyses. All statistical analysis methods used SPSS Statistical Analysis Software 
(SPSS, IBM, Chicago, IL, USA).  
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5.3 RESULTS 
5.3.1 Masson’s Trichrome Lesion Assessment 
Masson’s trichrome was used as an evaluative histologic stain as it can detect collagen present in 
the ECM bioscaffolds as well as some levels of glial scar components.  The lesions for all SCIs 
appear smaller at the dorsal edge of the spinal cord and grow in size towards the ventral region.  
Dorsal images were taken from 0 - 400μm, central from 500-700μm, and ventral beyond the 
700μm marker. All ECM scaffolds maintain a fibrous structure throughout the volume of the 
lesion as compared to the pepsin control. UBM-ECM maintains a consistent fibrous architecture 
within the lesion volume across all time points.  Samples injected with the pepsin digestion 
buffer contain less fibrous structure at the lesion site. A dense mononuclear cell accumulation 
can be seen in all accounts, with the ECM bioscaffolds supporting this cell infiltration 
throughout the wound lesion up to 28 days post injury (Figure 32).  
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Figure 32. Trichrome staining of UBM, B-ECM, SC-ECM treated spinal cords as compared to a pepsin 
buffer control.  All ECM scaffolds maintain a fibrous structure throughout the volume of the lesion as 
compared to the pepsin control. 
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5.3.2 Temporospatial Macrophage Evaluation 
A macrophage temporospatial analysis was completed using M1 marker CD86 and M2 marker 
CD206 with CD11b as a pan macrophage marker.  Representative images shown in Figures 33-
36, were taken from the central region of the spinal cord to demonstrate the macrophage spatial 
locations over the 7, 14, and 28 day time points.  All spinal cords contained a dense population 
of CD11b positive cells throughout the lesion area. All treatments show cells expressing CD206 
and CD86.  Pepsin buffer controls exhibit low levels of CD206 that maintain constant over 28 
days.  By 28 days, the CD86 positive cells are diffuse throughout the lesion site (Figure 33).  
Spinal cords treated with UBM-ECM shows a dense accumulation of CD206 positive cells over 
28 days.  CD86 positive cells are maintained throughout the 28 days (Figure 34).  B-ECM 
treatment animals displayed a moderate CD206 expression at 7 and 14 days post injury, however 
the CD206 expression becomes more diffuse by day 28.  CD86 cell population was present 
throughout the spinal cords at all time points (Figure 35).  SC-ECM shows a dense expression of 
CD206 and CD86 positive cells throughout the lesion site, however by day 28 the expression 
localized to the edge of the lesion (Figure 36).     
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Figure 33. Pepsin buffer control macrophage response over 28 days following injury.  The pepsin treated 
animals show CD206 expression, and a dense accumulation of CD86 positive cells at day 28. 
 
 
 
Figure 34. SCI repair with UBM-ECM over 28 days showed a dense accumulation of CD206 positive cells 
that maintained over 28 days.  The CD86 positive cells were diffuse through the lesion area throughout the 
time points examined. 
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Figure 35. SCI repaired with B-ECM showed a moderate CD206 population that became more diffuse by 28 
days.  The CD86 cell population is present throughout the lesion site. 
 
 
 
Figure 36. SCI repaired with SC-ECM shows dense CD206 and CD86 cell populations throughout the lesion 
at days 7 and 14.  By day 28, CD206 positive cells were found closer to cavity edges, whereas CD86 remained 
diffuse. 
 100 
5.3.3 Locomotor and Sensorimotor Recovery 
Assessment of locomotor and sensorimotor recovery was evaluated through 3 comprehensive 
behavioral recovery metrics.  The first, BBB scoring (Figure 37), showed no differences through 
28 days of evaluation.  The second, gridwalk horizontal ladder assessment showed large variance 
in groups and no differences between treatments at 14 (Figure 38) and 28 (Figure 39) days post 
injury.  The third metric was the Digigait paw analysis that evaluated stride length (Figure 40), 
paw angle (Figure 41), step angle (Figure 42), and limb stance width (Figure 43). While there 
were no behavioral differences between treated and untreated control in this metrics, there was a 
trend to increase the limb stance width for animals that underwent injury (Figure 43).  
 
 
 
Figure 37. BBB open field locomotor assessment shows all animals recovering to approximately a 12 on the 
BBB scale.  There are no differences between injury controls and treatment groups.  Additional controls were 
added to the graph that include laminectomy only, PBS injection, and contusion with no injection.  
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Figure 38. At 14 days post injury, there are no sensorimotor differences between treatment groups as shown 
through the gridwalk analysis. 
Figure 39. At 28 days post injury, gridwalk slip analysis shows no differences between treatment groups and 
injection buffer control. 
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Figure 40. Digigait stride length assessment between CNS-ECM and a non-CNS ECM scaffold show no 
differences between treatment groups and controls. 
Figure 41. Digigait paw angle assessment shows no difference between the uninjured control, pepsin, UBM-
ECM, B-ECM, and SC-ECM. 
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Figure 42. Digigait fore and hind limb step angle assessment shows no difference between uninjured animals, 
pepsin control, or ECM treatment groups. 
Figure 43. Digigait assessment of limb stance width shows a moderate increase in the hind limb stance width 
between uninjured and injured animals.  There are no differences between injury controls and treatment 
groups. 
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5.4 DISCUSSION 
In this study, injectable bioscaffolds derived from decellularized whole tissue and organ ECM 
were successfully delivered to the spinal cord following traumatic injury via syringe injection.  
Implantation of acellular ECM scaffolds has shown promise for treatment of traumatic neural 
injuries by promoting locomotor recovery, remyelination, and stimulated regenerative neural 
fibers (128, 129, 192, 252, 253). These promising benefits of ECM bioscaffolds for CNS 
applications may be due, in part, to the ability of the ECM scaffold to promote innervation 
following tissue reconstruction and recruit cells that play a role in neural repair (122). The SCI 
models previously evaluated with ECM bioscaffolds were either hemi- or transection.  In models 
such as these, the wound area is debrided before the implantation of acellular constructs that 
replace whole segments of the cord.  While this previous research demonstrated functional 
improvements, the removal of a segment of the spinal cord may not be as clinically relevant as a 
contusion injury model.  Further, the studies did not evaluate the role of the immune response to 
aid in tissue reconstruction.  
In this study, following a severe contusion injury, the lesion area of the spinal cords were 
first evaluated through a histologic examination of the lesion site using Masson’s trichrome 
staining.  The staining revealed a dense fibrous architecture found at the center of the lesion 
volume for all ECM scaffolds, while this structure was not present or reduced for the pepsin 
digestion control samples.  Further, a dense mononuclear cell population was associated with the 
lesion site throughout 28 days for all treatment groups.  While this dense mononuclear cell 
population is classically associated with inflammation, it has recently been seen as a step in ECM 
mediated tissue remodeling (222).  To further examine this mononuclear cell population, an 
evaluation of the macrophage/microglia phenotype was completed.   
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The present study evaluated the temporospatial macrophage/microglia response to SCI 
repair to injectable ECM scaffolds.  M2 polarized macrophages were present most commonly at 
the edge of, and often, in the center of the lesion over 28 days.  M1 macrophages, on the other 
hand, were evenly distributed surrounding and within the lesion. Center of the lesion was found 
using brightfield imaging and macrophage/microglia phenotyping was completed at this location.  
ECM bioscaffolds all maintained a CD206 cell population at the lesion site, however only UBM-
ECM maintained a dense accumulation over 28 days.  Previous research demonstrated that 
macrophages can be polarized towards an M2 phenotype at the edge of a lesion by the 
proteoglycan glial scar (254-256).  This phenomenon may explain the high levels of CD206 
positive cells at the cavity boundary.  ECM bioscaffold composition has also been shown to 
contain proteoglycans and future research should evaluate the role that the glycosaminoglycans 
and their degradation products play in creating a permissive environment for alternative 
macrophage activation.  The macrophages polarized towards an M2 phenotype in models of SCI 
have been shown to decrease secondary injury and size of lesion cavity (257).  Although the 
microenvironment was permissive for M2 macrophages, no ECM scaffold mediated behavioral 
recovery was found 28 days post injury.  Further, there did not appear to be a benefit for the use 
of site specific CNS-ECMs in this model. 
5.5 CONCLUSIONS 
ECM bioscaffolds can be syringe injected into the center of a SCI lesion and maintain a fibrous 
architecture within the lesion site. The fibrous structure within the lesion supported cellular in-
growth and a dense mononuclear cell accumulation.  No significant benefit was found for the use 
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of CNS-ECM scaffolds in either maintaining structure at the lesion site or with the dense 
mononuclear cell accumulation. While many of the mononuclear cells present at the lesion were 
M1 macrophages, M2 positive cells were also associated with the lesion site. In combination 
with other therapeutics, the ability to maintain a fibrous structure and promote cellular in-growth 
within the lesion site could be harnessed for spinal cord tissue reconstruction efforts.  
5.6 LIMITATIONS AND FUTURE WORK 
A major limitation of this work was the singular markers for the M1 and M2 evaluation.  The 
markers CD86 and CD206, while commonly used for M1 and M2 macrophage profiling, 
respectively, do not provide a complete profile of the current activation state. Future work should 
evaluate a gene expression profile, such as the one completed by Kigerl et. al. in 2009.  In this 
experiment, a set of markers including CD206, CD163, and arginase 1 could be used to evaluate 
M2 polarization and iNOS, CD16, CD86 could be examined to determine M1 functional 
upregulation (60).  A second limitation when evaluating the innate immune response was the 
lack of understanding how macrophages versus microglia played a role following ECM 
implantation.  As research continues to shed light upon the differential behaviors of macrophages 
and microglia, understanding the role that each plays in promotion of constructive CNS 
remodeling following ECM implantation is crucial (61). Future studies should be conducted with 
transgenic animals in models of SCI that can interrogate this crucial information.  While these 
limitations did not allow for a complete profile of the activation state for macrophage 
polarization, the results showed a comprehensive temporospatial analysis of the 
macrophage/microglia polarization and showed M2 macrophages can be found at the lesion site 
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28 days post injury.  This suggests that future work should include the evaluation of ECM 
bioscaffolds in other models of traumatic injury including stroke and TBI.   
The final limitation in this study was the hyper acute injection of the ECM bioscaffolds, 
which is not as realistic as waiting a short period or evaluating the materials in a chronic lesion. 
Future work should evaluate ECM bioscaffolds in a chronic model where the lesion has been 
allowed to form.  This would allow for the ECM bioscaffolds to be injected as a liquid and fill an 
irregularly shaped three-dimensional lesion commonly found in CNS pathology. The hydrogels 
would then provide a form filling scaffold for the infiltration of neural and immune cells.   
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6.0  DISSERTATION SYNOPSIS 
6.1 MAJOR FINDINGS 
The present work described the development, production, and use of CNS-ECM bioscaffolds as 
CNS therapeutics.  When the development of these scaffolds began there was only study on the 
isolation of brain derived extracellular matrix for angiogenic applications.  The formulation of 
CNS-ECM bioscaffolds into hydrogel materials made them appropriate for clinical application as 
minimally invasive surgical procedures could be used.  Compositional analyses demonstrated 
differences between ECMs isolated from different parts of the CNS, and mechanical evaluations 
of both brain and spinal cord ECM bioscaffolds demonstrated properties similar to the native 
CNS.  Brain, spinal cord, and UBM-ECM hydrogels supported extensive in-vitro three-
dimensional neurite extension as well as promoted differential differentiation, mitogenic, and 
chemotactic effects as demonstrated through stringent assays completed with human 
macrophages and spinal cord stem cells. Finally, the scaffolds were evaluated in a rat model of 
contusion spinal cord injury.  While no functional recovery was shown in this model of 
contusion SCI and hyper-acute repair with ECM bioscaffolds, a fibrous tissue structure that 
supported cellular in-growth was found at the center of the lesion that could be harnessed in 
combinatorial therapies for neural tissue reconstruction applications. 
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The following are major findings of the present work: 
Specific Aim 1 
• Brain and spinal cord ECM can be harvested from whole porcine tissue sources 
through decellularization that removes residual cells and DNA 
• Presence of extracellular matrix molecules including: laminin, soluble collagens I-
IV, growth factors VEGF and bFGF, sGAGs, and myelin 
• Neurotrophic potential within CNS-ECMs increases model neural cell 
differentiation responses 
• Formulation into injectable hydrogel materials with tunable mechanical properties 
that supports three-dimensional neurite extension 
Specific Aim 2 
• SPC response to CNS-ECMs and UBM-ECM shows unique properties of each 
ECM to influence mitogenesis, chemotaxis, and neuronal and astrocyte 
differentiation, with UBM promoting the most neuronal differentiation as denoted 
by β3-tubulin staining 
• Only M2 macrophages are chemotactic towards UBM-ECM 
• Increases in Fizz1 expression in an in-vitro mouse model of macrophage 
polarization in response to UBM-ECM and CNS-ECM degradation products 
suggest a component of the ECM that is conserved between tissue types can 
modulate macrophage phenotype 
Specific Aim 3 
• CNS-ECM hydrogel scaffolds can be successfully delivered to the site of SCI 
using syringe injection techniques 
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• A fibrous tissue structure was maintained within the lesion for ECM bioscaffolds 
• The fibrous tissue structure supports cellular in-growth into the lesion site  
6.2 OVERALL CONCLUSIONS 
The work contained in this dissertation describes the isolation and characterization of ECM 
derived from whole brain or spinal cord tissue.  The novel decellularization process described 
herein maintained ECM structural and bioactive molecules known to be neurotrophic and 
capable of supporting in-vitro three-dimensional neural growth. Hydrogels developed in this 
dissertation can be applied as neural therapeutics using minimally invasive surgical techniques 
and could be used in the future for combinatorial therapies that deliver pharmaceutical agents 
and or cells for cellular therapy. While ECM bioscaffolds did not improve behavioral outcomes 
following hyperacute injection, a permissive microenvironment was created for cellular in-
growth into the lesion site.  This research sets the foundation for future evaluation of bioscaffolds 
in traumatic neural injuries including stroke and traumatic brain injury.   
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